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Introduction to the Thesis 
 
One of the most important and unsolved problems in the therapy of pancreatic 
tumors is the development of resistance to pharmacological treatments. Inefficacy of 
therapies leads to the progression of these cancers, worsening the quality of life and 
shortening the lifespan. 
Tumors that interest the pancreas are quite different from each other, depending 
on the cell type by which it origins and on the alterations of pancreatic functionality. 
They may be classified in two groups: endocrine tumors, which arise from pancreatic 
endocrine cells, and carcinomas, which derive from cells with exocrine functions. 
Cancers derived from these two groups are very different in terms of prognosis. 
Indeed, pancreatic endocrine tumors are defined as “indolent”, due to their slow rate of 
growth and to the long survival of patients in most of the cases. On the contrary, 
pancreatic ductal carcinoma is considered one of the most lethal tumors, due to the 
inefficacy of chemotherapeutic treatment and by the short survival of patient. 
In both cases, tumors are incurable in most patients. The pharmacological 
approaches used for the treatment of endocrine or ductal tumors are different: in 
endocrine tumors, which have a slow progression rate, inhibitors of cell growth are used 
in the majority of cases, while in ductal carcinomas, which have a faster progression, 
chemotherapy with agents that impair replication of cancerous cells is preferred. 
The aim of the work presented in this thesis was to investigate the mechanisms 
at the basis of drug resistance in pancreatic tumors. The first part of the work is focused 
on the study of endocrine tumors and it proposes a novel strategy to counteract the 
problem of resistance of pharmacological treatment with Everolimus, using in vitro 
models. The second part of the work concerns the investigation of the molecular 
features of pancreatic ductal cancer cells, and how these mechanisms may be involved 
in the malignity of cancer cells and in the acquisition of resistance to chemotherapy. 
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CHAPTER I 
 
Pancreatic Endocrine Tumors  
 
Pancreatic Endocrine tumors (PETs) are a rare class of heterogeneous 
neoplasms, which represent only 1-2 % of all pancreatic malignancies (Fraenkel et al., 
2012). PETs arise from the endocrine cells which take part of the diffuse neuroendrocrin 
system of pancreas, whose main function is to produce several hormones, as insulin and 
glucagon. Despite their low incidence, PETs display 10% prevalence among patients 
affected by pancreatic tumors (Fitzgerald et al., 2008). The high percentage of 
prevalence is due to the “indolent” behaviour of PETs, which permits a long survival of 
patients. However, two thirds of patients display metastasis at time of diagnosis, 
becoming not amenable for surgery (Sadaria et al., 2013). 
Although the long survival of patients and the slow rate of growth of these 
tumors, the therapeutic approaches currently in use are not effective for the cure of 
PETs,  highlighting the needing of novel therapy for the management of these tumors. 
 
1.1 Classification and symptoms of PETs 
PETs are typically classified in two groups: 
• Functioning tumors 
• Non functioning tumors 
This subdivision is based on the ability of the tumor to secret hormones. 
Moreover, the classification of functioning tumors depends from the hormones 
produced. Most functioning endocrine tumors are considered “silent”, due to the low 
amount of hormones produced or for the release of inert precursors of hormones (Metz 
and Jensen, 2008). 
 
1.1.1 Functioning tumors 
The most common functioning tumors are insulinomas, gastrinomas, 
glucagonomas, VIPomas and somatostatinomas. 
• Insulinoma: it is the most common among PETs and it is characterized by the 
over-production of insulin, which causes hypoglycemic symptoms. Insulinomas 
are present in 10% of patient affected by Multiple Endocrine Neoplasia 1 
(MEN1) syndrome, an authosomal recessive disease characterised by the onset 
of several tumors in endocrine organs. This kind of tumor, which may arise 
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within the entire body of pancreas, in 90% of cases is benign and characterized 
by small size (0,5-2 cm). Since the high percentage of benign features of 
insulinomas, patients have a long term-survival. (Grant et al., 2005; Fendrich et 
al., 2009) 
• Gastrinoma: it is responsible of Zollinger-Ellison syndrome, a complex disease 
characterised by the secretion of gastrin, which leads to an over-production of 
gastric acids. Zollinger-Ellison syndrome is the second most frequent PET, and 
in 80% of cases it is a sporadic tumor, while in 20% of patients it is associated to 
MEN1 syndrome. Gastrinomas may occur in duodenum or in pancreas and they 
are characterised by slow growth, albeit in 60-70% of cases are malignant and 
most patients present with metastases at time of diagnosis. Time of survival of 
patients depends on the presence of liver metastasis. Indeed, in the absence of 
metastasis, survival of 95% of patients is grater than 20 years (Yu et al., 1999; 
Krampitz and Norton, 2013).  
• Glucagonoma: this disease is characterized by an hyper-production of glucagon. 
Therefore, patients affected by glucanoma present a complex medical spectrum. 
This disease is in the majority of the cases malignant, and patients often present 
as metastatic at time of diagnosis, becoming not eligible for surgery (Bornman et 
al., 2001; Doherty et al., 2005). 
• VIPoma: this tumor, arising in the tail of pancreas, is characterised by the 
production of high level of Vasoactive intestinal peptide (VIP). VIP is able to 
activate endothelial cells of intestine, thus inducing the up-take of electrolytes 
and water (Laburthe et al., 2002). For this reason, VIPomas are associated to 
watery diarrhea. 80% of patients with VIPomas, which may be associated to 
MEN1 syndromes, present with metastases at time of diagnosis (Ito et al., 2012; 
Krampitz and Norton, 2013).  
• Somatostatinoma: is characterised by the production of high amount of 
somatostatin that is released at high levels in blood stream. Diagnosis of this 
kind of tumors often occurs lately, due to the complexity of the medical case. 
Indeed high levels of somatostatin induce inhibition of pancreatic exocrine 
activities and of the release of gastrin, which is important for the production of 
hypocloridric acid in stomach. In two thirds of somatostatinomas, metastases are 
present at time of diagnosis (Ito et al., 2012; Krampitz and Norton, 2013). 
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1.1.2 Non Functioning tumors 
Non functioning PETs (NF-PETs) do not cause syndromes associated with over-
production of hormones, albeit NF-PET may produce other substances that do not lead 
to symptoms. The most common hormones produced by NF-tumors are chromogranin 
A, teurotensin and pancreatic enzymes. These tumors may also produce low levels of 
insulin, glucagon and other pancreatic hormones.  
Due to the absence of symptoms, 60% of patients with NF-PETs present liver 
metastases (Metz and Jensen, 2008), thus influencing long-term survival, which is 20-
30% after 5 years from initial presentation (Akerström and Hellman, 2007, Fendrich et 
al., 2009). 
   
1.2 Diagnosis 
Imaging techniques have an important role in the diagnosis of PETs, which are 
required also for the localization, staging and monitoring of diseases. The most 
important problem during the diagnosis is the small dimension of this type of tumors. 
Computed tomography (CT) is used for the detection of PETs with a diameter inferior 
to 2 cm. Magnetic resonance imaging (MRI) is able to detect tumors smaller than 2 cm 
and metastases, whereas endoscopic ultrasonography (EUS), can detect very small 
tumors (< 1 cm), undetectable by MRI and CT. Moreover, EUS can guide biopsy of 
tumors and provide histological diagnosis. Somatostatin receptor scintigraphy 
(Octreoscan, SRS) is used to detect functioning and non-functioning tumors expressing 
high level of somatostatin receptors through radiolabeled somatostatin analogs. 
However, SRS is not able to detect insulinomas or non-functioning tumors that express 
low level of somatostatin receptors. 
Moreover, diagnosis requires the analysis of the levels of hormones in serum of 
patients. This kind of analysis allows a better identification of the features of tumor 
(Kramptiz and Norton, 2013). 
 
1.3 Therapy 
Surgical resection is the first line treatment for PETs and it guarantees good 
prognosis in patients with no evidence of metastatic disease.  Indeed, surgical approach 
depends on the location of the tumor, size and the presence of metastases. In patients 
with no evidence of hepatic or linfonodal metastases, surgery is recommended to 
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resolve symptoms of tumors and to increase 5-year survival from prognosis (Yalcin et 
al., 2011). 
Surgical therapy is supported by non-surgical approach, in order to monitor both 
tumor size and symptoms. Chemoterapy is not used as first line treatment for PETs, due 
to the low rate of tumor growth, albeit several trials have been employed for advanced 
metastatic PETs. 
In the last years, novel target therapies have been considered for the treatment of 
PETs. Indeed, molecular characterization of these neoplasms has permitted to identify 
novel molecular targets and to develop target therapies for the treatment of PETs. PETs 
show a strong expression of vascular endothelial growth factor receptors (VEGFR) and 
they are characterized by strong vascularisation and induction of angiogenesis (Corbo et 
al., 2012). For this reason, novel inhibitors that target angiogenesis, as Sunitinib, have 
been employed for PET treatments. Sunitinib was approved by the Food and Drug 
Administration (FDA) for the treatment of advanced metastatic PanNET, due to the 
improvements in prolongation of life (Blumenthal et al., 2012). It targets several kinases 
involved in angiogenesis, such as VEGFR, PDGFR, c-KIT and RET (Mendel et al., 
2003). However, beside its demonstrated antitumor activity, clinical trials have shown 
that Sunitinib also exerts side effects in patients. 
Studies on tissues and cell lines derived from PETs patients demonstrated that 
the PI3K/AKT/mTOR pathway, which regulates protein synthesis and cell proliferation, 
is frequently de-regulated in this type of tumors (Missiaglia et al., 2010, Di Florio et al., 
2007, 2011; Yao et al., 2011; de Wilde et al., 2012). For this reason, the use of 
inhibitors specific for this pathway, such as Everolimus, has been considered for the 
treatment of PETs. Everolimus, was approved for the treatment of advanced PETs by 
FDA in 2011 (Yao et al., 2011), and after preclinical studies, which demonstrated the 
positive effect of Everolimus on survival (Chiu et al., 2010), this drug was employed for 
advanced PETs. Notably, Everolimus showed a significant effect on progression-free 
survival of patients (Yao et al., 2011), thus providing a novel therapeutic approach for 
this class of tumors. 
 
1.4 Molecular characterization of PETs 
Some evidences of genetics and/or molecular alterations in PETs have been 
reported. Most of these heterogeneous diseases arise from patients affected by different 
genetic syndromes, while the pathogenesis of sporadic tumors depends from mutations 
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or aberrant expression of oncogenes and alteration in pathways that regulate cell 
proliferation and cell metabolism (Capurso et al., 2012). 
The most frequent inherited genetic syndromes involved in PETs are Multiple 
Endocrine Neoplasia Type 1, Von Hippel Lindau Disease, Tuberous sclerosis complex 
and Neurofibromatosis Type 1. However, most of the mutations responsible for genetic 
syndromes associated with PETs arise also in sporadic cases of this class of tumors, in 
addition with other mutations that are not typical of genetically linked PETs. 
 
1.4.1 Genetic Diseases associated with PETs 
 
Multiple Endocrine Neoplasia Type 1 (MEN1) 
MEN1 is an autosomal dominat disease characterised by the appearance of 
several neuroendocrine tumors in gastro-entero-pancreatic organs (Lemos and Takkher, 
2008). The disorder is caused by mutations in the MEN1 gene, located in chromosome 
11q13, which inactivates the function of the protein encoded by the gene: Menin (Metz 
and Jensen, 2008). It was reported that 10% of patients affected by PETs have MEN1 
syndrome (Metz and Jensen, 2008). Menin is important for the modulation of the 
expression of genes involved in the regulation of cell cycle at the trancritptional level, 
such as p27 and p18 genes (Karnik et al., 2005), by promoting their methylation (Wu et 
al., 2011). Indeed, Menin takes part to the mixed lineage leukemia (MLL) histone 
methyl transferase complex, and it is required for the H3K4 methyltrasferase activity of 
the MLL complex (Murai et al., 2011; Karnik et al., 2005).  Mutations in the MEN1 
gene often impair protein nuclear localization (Corbo et al., 2010), thus causing its 
down-regulation. Moreover, Menin down-regulation also depends on the activation of 
PI3K/AKT pathway. In fact, activation of this pathway promotes FOXO1 expression, 
which in turns binds the MEN1 promoter and suppresses its expression (Zhang et al., 
2012).  
 Loss of Heterozigosity (LOH) for MEN1 or mutations in both alleles of MEN1 
are frequent also in sporadic cases of PETs, and it was estimated that mutations in this 
gene affects about 44% of cases of sporadic PETs (Jao et al., 2011). The key role of the 
MEN1 gene in PET development was confirmed also in a mouse murine model of the 
disease, where homozygous deletion of the Men1 gene is embryonic lethal whereas its 
heterozygous deletion causes the onset of endocrine tumors, thus recapitulating the 
effect of MEN1 loss in human tumors (Crabtree et al., 2001).  
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All these observations enforce the key role played by loss of Menin function in 
the oncogenic process leading to PET development. 
 
Von Hippel Lindau Disease 
Von Hippel Lindau disease is an autosomal recessive disorder characterised by 
multiple tumors, including PETs (Libutti et al., 2000). This disorder is caused by 
mutations in the VHL gene, which encodes for two proteins derived from the splicing of 
VHL mRNA. Both VHL isoforms regulates the Hipoxia Inducible Factor a (HIF1α). In 
particular, VHL proteins form a α-ubiquitinase complex that interacts with HIF1α and 
leads to its degradation. Depletion of VHL induces HIF1α stabilization, which activates 
the transcription of genes involved in angiogenesis, a key feature of PETs (Lonser et al., 
2003). 
PETs arising from Von Hippel Lindau Disease represent a small fraction of 
tumors associated with this disorder (Mukhopadhyay et al., 2002), and they are often 
small and non-functioning tumors. Moreover, mutations or depletion of the VHL gene 
occurs with low frequency in sporadic tumors, albeit tumors arising from VHL 
mutations often show malignant features (Schmitt et al., 2009). 
 
Tuberous sclerosis complex (TSC1/TSC2) 
Tuberous sclerosis complex is a recessive autosomal disease associated with 
PETs. The rate of patients affected by this genetic disease is very low (Curatolo et al., 
2008). The genes mutated in tuberous sclerosis complex are TSC1 and TSC2, two 
important negative regulators of mTORC1 activity. Therefore, mutated TSC1/2 proteins 
were found also in sporadic PETs and in immortalized cell lines used as in vitro model 
for PETs (Missiaglia et al., 2010). Association of the genetic disorder of TSC to PETs is 
a strong indication of the role of the mTOR pathway on the progression of tumor 
transformation in PETs, and alterations of protein expression of TSC2 were found also 
in sporadic cases of PETs (Missiaglia et al., 2010). 
 
Neurofibromatosis Type 1 
Neurofibromatosis Type 1 is an autosomal disorder characterised by the 
occurrence of several tumors, including PETs. It derives from mutation in the NF1 
gene, which encodes for neurofibromin, a GTPase protein involved in the regulation of 
the RAS and mTOR pathway.  LOH or puntiform mutations inactivating the protein 
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function have been described in PETs (McClatchey et al., 2007), highlighting its 
involvement in progression of PETs.  
 
1.4.2 Sporadic Mutations associated with PETs pathogenesis  
The characterization of the genetic profiles of PETs and the association of these 
tumors with specific genetic disorders underline the recurrence of mutations as an 
important factor for the development of these tumors. In particular, mutations in genes 
associated with loss of proliferation control and angiogenesis are associated with PET. 
As mentioned above, the most frequent genes mutated in sporadic tumors are those 
associated with genetic syndromes. However, additional genes have been found mutated 
in PET patients, such as DAXX, ATRX, VEGF, PDGF, KIT,, Src family kinases, and 
components of the PI3K/AKT/mTOR pathway (discussed in a separated session). 
 
DAXX/ATRX 
The DAXX gene encodes for a histone chaperone that, in cooperation with 
ATRX, is involved in the regulation of telomere lengthening, and was found mutated in 
43% of PETs (Jiao et al., 2011). Thus, mutations in DAXX and ATRX affect genome 
stability and their impairement may provide the ability of undergo to unlimited cell 
cycling to cancer cells. Moreover, DAXX protein is also involved in regulation of p53 
activity. Indeed, DAXX promotes p53 stabilization, which in turn activates the G1/S 
check point. Hence, the loss of DAXX gene function leads to a loss of p53 activation 
and promotes tumor progression (Taguchi et al., 2011), thus suggesting a direct role in 
PET tumorigenesis. Nevertheless, in spite of their high frequency of incidence, 
mutations in DAXX and ATRX are not related with poor prognosis in PETs, as they are 
preferentially associated with well- or moderate-differentiated tumors (Jiao et al., 2011). 
 
VEGF/PDGF/c-kit 
PETs are characterised by extensive vascularisation, and deregulation of 
pathways involved in angiogenesis has a great relevance for the acquisition of this 
feature. One of the most important molecules required for angiogenesis in normal 
pancreatic cells is vascular endothelial growth factor (VEGF), whose expression is 
deregulated in many tumors. Increased angiogenesis is among the most critical features 
observed also in the Rip-Tag2 mouse model of endocrine tumors (Hanahan et al., 1985; 
Hanahan and Folkman, 1996). In light of these observations, several pathways involved 
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in angiogenesis have been analyzed in PETs. Receptors for molecules required for the 
formation of novel blood vessels, like VEGFRs, PDGFR and c-kit, were found over-
expressed in specimens of PETs (Fjallskog et al., 2003; Fjallskog et al., 2007). 
However, it was also found that the expression of VEGF was higher in well-
differentiated endocrine tumors with respect to low-differentiated tumors (Couvelard et 
al., 2005), together with higher presence of blood vessels respect with less differentiated 
tumors (Marion-Audibert, 2003). These data correlates with an higher level of HIF1-α 
protein in high grade-tumors (Couvelardet et al., 2005), which may provides advantages 
in terms of proliferation and survival to cancer cells. Thus, angiogenesis, which is a 
specific feature of PETs, may guide tumor progression trough the expression of specific 
pro-angiogenic factors.  
  
Src family tyrosine kinases 
Recently, a novel role for the oncogenic Src tyrosine kinase in PETs has been 
proposed. Src is the prototype of a large family of nine membrane associated-tyrosine 
kinases (Thomas and Brugge, 1997), the Src-family kinases (SFKs), which are involved 
in the transduction of extracellular stimuli. Src drives several cellular processes related 
to cancer, including cell metabolism, cell cycle control and migration (Thomas and 
Brugge, 1997). The involvement of SFKs in PETs was found initially on the increased 
level of Lck (a member of SFKs) in specimens of PETs (Capurso et al., 2006). More 
recently, it was found that Src protein is over-expressed in specimens of PETs with 
respect to normal tissue (Di Florio et al., 2007) and that Src controls PET cell adhesion 
and protein synthesis through the crosstalk with the mTOR pathway (Di Florio et al., 
2007; 2011). Collectively, these observations underline the relevance of Src activity in 
tumorigenic features of PETs. 
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CHAPTER II 
 
Role of the PI3K/AKT/mTOR pathway in PETs 
 
Regulation of cell metabolism is important for the activation or inhibition of 
several cellular functions. Cells must regulate their homeostasis through anabolic and 
catabolic reactions, which cooperate to control cellular growth, mRNA translation, 
proliferation and energy balance. The most important pathway involved in this 
regulation is the PI3K/AKT/mTOR one. 
This pathway is coordinated by the three kinases, Phosphatidylinositol-3-kinase 
(PI3K), Protein Kinase B (also known as AKT), and mammalian target of rapamycin 
(mTOR), which in turn take part of two different protein complexes, mTORC1  and 
mTORC2 (Figure 2.1).  
The extensive crosstalk between these kinases activates or inhibits cell growth in 
response to extracellular stimuli or various intra-cellular cues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Representative scheme of the PI3K/AKT/mTOR pathway. The signalling network 
coordinated by the pathway regulates cell growth, proliferation, ribosome biogenesis and protein 
translation ( From Hannan et al., 2011).  
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2.1 The PI3K/AKT/mTOR pathway 
 
2.1.1 PI3K 
PI3K  is a lipid kinase situated upstream of the entire pathway. It is involved in 
the transduction of external stimuli triggered by the activation of a large class of 
receptor tyrosine kinases (Hannan et al., 2011). The most important molecule that 
conveys the extracellular stimuli is phosphatidylinositol-3,4,5-trisphosphate (PIP3), 
whose phosphorylation sets in motion the downstream signalling cascade. Indeed, PI3K 
initiates the intracellular signal by phosphorylating phosphatidylinositol-4,5-
diphosphate (PIP2), a class of lipid enriched into the plasma membrane, in PIP3. Once 
produced, PIP3 binds proteins containing a PIP3-binding-motif, such as Pleckstrin 
Homology (PH) domain, thereby regulating protein relocalization to the plasma 
membrane, vescicle trafficking, cell proliferation and survival (Fruman et al., 2014). 
There are three classes of PI3K enzymes (Fruman et al., 2014), known as 
Classes I, II and III. Only the class I is able to phosphorylate PIP2 into PIP3, thus 
participating to the transduction of the signal. Indeed, Class II phosphorylates only 
phosphatydilinsositol or phospatydilinostitol-4-phospate, whereas Class III acts only on 
Phosphatydilinsositol. 
The activity of PI3K is determined by the release of the p110 catalityc subunit 
from the regulatory p85 subunit or by the activation mediated by Rat sarcoma (RAS) 
protein. RAS, which have a GTPase activity, is another factor involved in the 
transduction of extracellular and intracellular stimuli. It activates several pathway, the 
most important is the mitogen-activated protein (MAP) kinase pathway. However, RAS 
is able to converge signals into the PI3K/AKT/mTOR pathway, through the activation 
of PI3K. Several isoforms of PI3K catalytic and regulatory subunits have been 
characterized. They are classified in Class IA (P110α, β, δ and p85α, β, δ), which are 
typically activated by receptors with tyrosine kinase activity, and Class IB (p110γ and 
regulatory subunit p101), which are activated by G protein associated receptors 
(McNamara and Degterev, 2011). 
In line with the relevance of the signalling triggered by PIP3, PI3K activity is 
finely tuned in the cell. A major layer of regulation is comprised by protein-protein 
interactions and post-translational modifications of the subunits of the PI3K enzymes. 
For instance, the regulatory subunit of PI3K, through the interaction with receptors 
tyrosine kinase, controls activation and subcellular localization of catalytic subunit of 
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PI3K (Hay et al., 2005). In addition, activation of the PI3K/AKT/mTOR pathway is 
subject to a tight control by another protein, the phosphatase tensin homologue (PTEN), 
which is able to convert PIP3 to PIP2, thus switching off the signalling activated by 
PI3K (Song et al., 2012)  
 
2.1.2 AKT Kinase 
AKT kinases are the most important effectors of the PI3K pathway. AKTs 
crosstalk with several crucial pathways, that ultimately control cell proliferation and 
survival. Three AKT kinases (AKT1, AKT2 and AKT3) have been characterized and 
their phosphorylation in specific residues is required for full activation of the 
downstream pathway. AKT is indirectly activated by PI3K. Activation of PI3K 
determines an increase of PIP3 levels in the plasma membrane, which recruits and 
activates the 3'- phosphoinositide-dependent kinase 1 (PDK1). PDK1, in turn, recruits 
and phosphorylates AKT in Threonine 308 (T308), thus leading to partial activation of 
the kinase. However, a second phosphorylation event is required for the full activation 
of AKT. Indeed, a second residue, Serine 473 (S473), is targeted by another important 
complex, mTORC2, which leads to full activation of AKT (Manning and Cantley, 
2007). 
Several pathways are influenced by activity of AKT. For instance, it has been 
extensively documented how AKT regulates cell death, cell growth, proliferation and 
metabolism (Manley and Cantley, 2007). AKT is involved in the regulation of apoptosis 
by phosphorylating Caspase-3 and BAD proteins and inhibiting cell death (Datta et al., 
1997). AKT also phosphorylates the transcription factor FOXO, repressing transcription 
of pro-apoptotic genes (Van Der Heide et al., 2004). Furthermore, phosphorylation of 
the p53 binding protein MDM2 induces its translocation into the nucleus, where it binds 
p53, leading to degradation of p53 and promoting cell survival (Marine et al., 2010, 
Zhou et al., 2001). AKT is also known to regulate cell proliferation by phosphorylating 
GSK3β, which in turn regulates several processes. For instance, GSK3b regulates the 
stability of transcription factors involved in cell proliferation and survival such as, the 
activator protein 1 (AP-1), nuclear factor kappa B (NFκB), c-Myc and Snail (Buss et 
al., 2004; Yada et al., 2004, Yook et al., 2006). 
Importantly, AKT indirectly regulates the activation of the mTORC1 complex, 
which is crucial for protein synthesis. In particular, AKT interacts with and 
phosphorylates and inhibits TSC2, a component of the TSC complex, composed by 
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TSC1 and TSC2. TSC complex, which act as a GTP-ase activating protein (GAP) 
interacts with the Ras homolog enriched brain (Rheb), that activates mTOR when it is 
bound to GTP (Tee et al., 2003). The GTP-bound form of Rheb is inactivated when 
interacts with TSC complex, which converts Rheb to the GDP-bound form, thus 
inhibiting mTORC1 functions (Inoki et al., 2003). 
All these observations indicate that AKT has pro-survival functions and strongly 
suggest that its deregulation may favour pro-oncogenic properties. 
 
2.1.3 The mTOR protein, complexes and effectors 
Mammalian Target of Rapamycin, or mTOR, is a large protein that owes its 
name to the drug impairing its activity in yeast (Cafferkey et al., 1993; Kunz et al., 
1993) and in mammalian cells (Brown et al., 1994; Sabatini et al., 1994). Later, it was 
found that mTOR controls fundamental cellular process, such as ribosome biogenesis, 
protein synthesis and cell growth. Several years after its discovery, mTOR was found to 
be part of two protein complexes, involved in different activities, but cooperating within 
the same pathway (Figure 2.2). In the cell, mTOR is present in the mTORC1 complex 
(known as rapamycin-sensitive complex) (Kim et al., 2002; Loewith et al., 2002) and in 
the mTORC2 complex (rapamycin-insensitive complex) (Sarbassov et al., 2004; Jacinto 
et al., 2004). As mentioned above, mTORC1 is indirectly regulated by AKT, thus its 
activity is controlled by the PI3K/AKT axis and mTOR is generally situated 
downstream of these kinases in the pathway. The mTORC2 complex is another 
important regulator of PI3K/AKT/mTOR pathway. Indeed, it normally responds to 
growth factors and participates in the regulation of cell survival, metabolism, and 
cytoskeleton organization and its most known function is to promote the full activation 
of AKT by the phosphorylation in S473.  
The two complexes, mTORC1 and mTORC2, containing the mTOR protein 
differ for the interacting proteins (Figure 2.2). Indeed, in the mTORC1 complex mTOR 
interacts with RAPTOR and PRAS40, whereas the mTORC2 complex contains 
RICTOR, mSIN1 and PROTOR (only in higher eukaryotes) (Guertin and Sabatini, 
2007). Both complexes contain other proteins, such as DEPTOR, mLST8, tt1 and tel2. 
In the mTORC1 complex, RAPTOR is the activator of mTOR and it is antagonized by 
PRAS40, while, in the mTORC2 complex, both RICTOR and mSIN1 cooperates to 
activitate mTOR. 
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Figure 2.2 Scheme of cellular functions regulates by mTORC1 and mTORC2 complexes, and list of 
proteins contained in both complexes (modified from Laplante and Sabatini, 2012) 
 
 
The most studied complex for its role in the regulation of cell growth and 
metabolism is the mTORC1 complex. The mTORC1 complex is finely regulated by the 
upstream PI3K/AKT axis in response to several types of stimuli, such as growth factors 
or the energy status of the cell. As described above, AKT indirectly activates the 
mTORC1 complex by phosphorylating the TSC1/TSC2 complex, which inhibits the 
small GTPase Rheb. Thus, AKT removes the negative influence of TSC1/TSC2 and 
promotes Rheb-dependent activation of mTORC1. Moreover, AKT directly activates 
mTORC1 by phosphorylating mPRS40, which negatively regulates the complex (Haar 
et al., 2007). 
The multilayer nature of mTORC1 regulation highlights the important need for 
the cell to keep the activity of this complex under tight control. mTORC1 mainly 
phosphorylates effectors involved in protein synthesis and ribosome biogenesis, 
processes that require high energy consumption and have to be kept in balance with the 
availability of nutrients and the requirement of cells to grow in size and proliferate. The 
most studied function of mTORC1 is regulation of protein translation. mTORC1 
phosphorylates the eIF4E-Bindig protein 1 (4E-BP1) and the ribosomal protein S6 
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kinase 1 (S6K1). Phosphorylation of 4E-BP1 is required to disrupt the binding of 4E-
BP1 with eIF4E, the factor able to bind the 5’UTR of messenger mRNA and that 
promotes the assembly of the ribosome for the translation (Mamane et al., 2009). S6K1 
promotes protein synthesis through the activation of the scaffold protein eIF3, which 
binds messenger RNAs and leads to the assembly of ribosomal subunit 40S (Sonenberg 
and Hinnebusch, 2009).  
The activity of mTORC1 downstream effectors may, in turn, regulate upstream 
components of the PI3K/AKT pathway. For instance, when mTORC1 is active, S6K1 
exerts a negative feedback on the pathway by phosphorylating and the Insulin receptor 
substrate 1 (IRS-1) (Shah and Turner, 2006). In this way, IRS-1 is degraded and PI3K 
signalling is attenuated. When mTORC1 activity in blocked for nutrient deprivation or 
pharmacological inhibition, the pathway can be stimulated through reactivation of IRS-
1 and RTK signalling, which both turn on PI3K/AKT axis (Hay et al., 2005).  
Due to its central role in regulation of protein synthesis, cell growth and many 
other important cellular functions (Laplante and Sabatini, 2012), mTORC1 was 
extensively studied in tumorigenesis, and it represents one of the most important targets 
for the pharmacological treatments of human cancers. 
 
2.2 Deregulation of PI3K/AKT/mTOR in PETs 
The PI3K/AKT/mTOR pathway was found deregulated in a high percentage of 
PETs. Notably, mutations in negative or positive regulators of the pathway, or 
alterations of the key components of the axis were associated to this class of diseases. 
For instance, the expression and localization of the main negative regulator of 
the PI3K/AKT/mTOR pathway, PTEN, was found deregulated in primary samples of 
PETs (Missiaglia et al., 2010). Furthermore LOH in PTEN was associated to malignant 
features of PETs (Perren et al., 2000; Han et al., 2013), indicating its involvement in the 
oncogenesis of these endocrine tumors.  
Other negative regulators of the PI3K/AKT/mTOR pathway were found mutated 
in primary samples of PETs. One of the most known negative regulators whose 
mutation is associated with these tumors is TSC2. Indeed, mutations in genes of the 
TSC complex are known to cause the genetic syndrome of Tuberous Sclerosis, which is 
also associated with PETs (Larson et al., 2012; Arva et al., 2012). Furthermore, in PETs 
that are not associated with these genetic syndromes, TSC2 expression was down-
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regulated and its low expression correlated with poor prognosis (Missiaglia et al., 
2010). 
The activity of AKT has been extensively studied in PETs, due to its 
involvement in the activation of pro-survival pathways. AKT was found up-regulated in 
over 60% of PETs (Ghayouri et al., 2010), indicating a positive correlation with the 
disease. Moreover, AKT activation is able to inhibit the expression of MEN-1 gene 
(Zang et al., 2012), and at the same time, depletion of MEN-1 promotes the activation 
of AKT downstream signals (Wang et al., 2011).  
mTOR protein activity and its effectors are also frequently deregulated in PETs. 
For instance, high levels of p-mTOR were found in PETs samples (Zhou et al., 2011, 
Komori et al., 2014). Moreover, the expression of the mTOR effectors is aberrant in 
PET patients. For instance, higher levels of phosphorylated 4E-BP1 (p-4EBP1) were 
correlated with poor outcome (Di Florio et al., 2011) and deregulation of the mTOR 
pathway was also observed in PET cell lines (Missiaglia et al., 2010; Di Florio et al., 
2011). 
Collectively, these data underline the importance of perturbation of the 
PI3K/AKT/mTOR pathway in PETs and suggest that this pathway is a suitable 
therapeutic target to counteract progression of PET cancer cells. 
 
2.3 Inhibitors of PI3K/AKT/mTOR in PETs 
Preclinical studies on pharmacological inhibition of mTOR in neuroendocrine 
tumors (Chiu et al., 2010; Moreno et al., 2008) encouraged the research of novel 
therapeutic approaches acting on this important kinase. Preliminary studies on patients 
affected by PETs, demonstrated that pharmacological inhibition of mTOR exerted a 
significant effect on survival (Yao et al., 2008; Yao et al., 2010). The drug used for the 
studies was Everolimus (RAD001, Novartis), which was approved by Food and Drug 
Administration for the treatment of advanced endocrine tumors (Yao et al., 2011). 
Everolimus, as well as other molecules derived from rapamycin (rapalogs), acts as an 
allosteric inhibitor by binding and inactivating FKBP12, a protein that in turn activates 
mTOR in the mTORC1 pathway (Faivre et al., 2006) (Figure 2.3). 
However, despite improvements in prolongation of life, some patients display a 
primary resistance to the drug and do not respond to Everolimus (Capurso et al., 2015). 
To date, the causes of primary resistance to the treatment are not known. Moreover, a 
quote of patients treated with Everolimus acquires a secondary resistance to treatments, 
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indicating that cancer cells can develop the ability to grow in presence of mTORC1 
inhibition during chronic therapeutic treatments. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Molecular structure of Rapamycin. The figure shows the binding site of FKP12 and mTOR. 
In pink it was evidenced the portion of the molecule that has been modified to convert rapamycin in other 
affine molecules (rapalogs) (Modified from Faivre et al., 2006) 
 
Pharmacological inhibition of mTOR using rapamycin analogues such as 
Everolimus, causes a feedback reactivation of PI3K/AKT pathway (Laplante and 
Sabatini 2012; Meric-Bernstam et al., 2012), leading tumor cells to escape from mTOR 
block. In particular, increased phosphorylation of AKT promotes prosurvival responses 
that may allow cells to withstand treatment with Everolimus and other rapalogs. .  
These observations suggest that novel therapeutic approaches are required to 
counteract primary and acquired resistance to Everolimus in PET patients. Since 
feedback activation of AKT is likey involved in such resistance (Meric-Bernstam et al., 
2012) treatment with inhibitors of PI3K was thought to possibly prevent the activation 
of such pro-survival pathways in patients treated with Everolimus. 
Three novel inhibitors of PI3K have been proposed for the treatment of PETs, 
and  recently tested in pre-clinical and clinical studies as anti-cancer treatments 
(Capurso et al., 2012) (Figure 2.4): 
• BEZ235: this inhibitor is classified as dual inhibitor, as it inactivates all the 
PI3K class I isoforms but it also binds to the catalytic site of mTOR, thus 
potentially blocking both mTORC1 and mTORC2 (Maira et al., 2008); 
• BKM120: This inhibitor is specific for the class I PI3K isoforms (Koul et al., 
2012) 
• BYL719: This inhibitor is specific for the p100α isoform of PI3K (Furet et al., 
2013). 
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Figure 2.4. Schematic representation of the targets of the inhibitors BEZ235, BKM120 and BYL719. 
 
The use of these novel PI3K inhibitors, either alone or in combination with Everolimus, 
has been considered a potentially valuable tool to avoid the mechanisms of resistance to 
mTORC1 inhibition, in order to avoid resistance to Everolimus treatment.  
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CHAPTER III 
 
Combined treatment with RAD001 and BEZ235 overcomes resistance 
of PET immortalized cell lines to mTOR inhibition 
 
Pancreatic endocrine tumors (PETs) are characterised by an indolent behaviour 
in terms of tumor growth. However, at time of diagnosis most patients present with 
metastatic disease and they are not eligible for surgical treatment. Molecular evidence 
suggests that the PI3K/AKT/mTOR pathway is deregulated in PETs. In light of this, 
Everolimus (RAD001), which inhibits specifically mTOR, is used as pharmacological 
approach in PET therapy. However not all patients respond to the treatments, and most 
patients that initially respond eventlually develop resistance to Everolimus. 
Chronic inhibition of mTOR may lead to a feedback re-activation of PI3K 
activity, thus restoring the PI3K/AKT axis functionality and providing an escape route 
to cancer cells. For this reason, PI3K became a novel important target in order to 
counteract the resistance to mTOR inhibition, and its specific inhibition has been 
considered as potential therapeutic approach for PETs. 
In our work, we tested three novel PI3K inhibitors (BEZ235, BKM120 and 
BYL719) in three cell lines used as a model for PETs tumors. In particular we tested 
the inhibitors in cells that respond to Everolimus (BON-1), cells unresponsive to the 
drug (QGP-1) and cells that acquired resistance to Everolimus after a chronic 
treatments of 8 weeks (BON-1 RR). We found that BEZ235 was the most efficient in 
term of inhibition of cell proliferation in all cell lines analyzed. Moreover, combined 
treatment with BEZ235 and RAD001 exerted a synergic effect on inhibition of cell 
proliferation with respect to treatment with single agents alone. Analysis of the 
PI3K/AKT/ mTOR pathway demonstrated that combined treatment significantly 
affects the phosphorylation of 4EBP1, indicating that the effect on cell proliferation 
might rely on the inhibition of the translation machinery. Indeed, we found that 
combined treatment affects the assembly of the translation initiation complex and, 
consequently, it significantly impairs protein synthesis as compared with treatment by 
single agents.  
Our results suggest a novel approach in the treatment of PETs. Indeed, our 
study documents that targeting of mTOR with Everolimus and BEZ235 could 
overcome resistance to mTOR inhibition, providing a novel suitable therapy to 
counteract primary and secondary resistance to Everolimus in PETs. 
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ABSTRACT
Pancreatic endocrine tumors (PETs) are characterised by an indolent behaviour 
in terms of tumor growth. However, most patients display metastasis at diagnosis 
and no cure is currently available. Since the PI3K/AKT/mTOR axis is deregulated in 
PETs, the mTOR inhibitor RAD001 represents the first line treatment. Nevertheless, 
some patients do not respond to treatments and most acquire resistance. Inhibition of 
mTOR leads to feedback re-activation of PI3K activity, which may promote resistance 
to RAD001. Thus, PI3K represents a novel potential target for PETs. We tested the 
impact of three novel PI3K inhibitors (BEZ235, BKM120 and BYL719) on proliferation 
of PET cells that are responsive (BON-1) or unresponsive (QGP-1) to RAD001. BEZ235 
was the most efficient in inhibiting proliferation in PET cells. Furthermore, combined 
treatment with BEZ235 and RAD001 exhibited synergic effects and was also effective 
in BON-1 that acquired resistance to RAD001 (BON-1 RR). Analysis of PI3K/AKT/
mTOR pathway showed that RAD001 and BEZ235 only partially inhibited mTOR-
dependent phosphorylation of 4EBP1. By contrast, combined therapy with the two 
inhibitors strongly inhibited phosphorylation of 4EBP1, assembly of the translational 
initiation complex and protein synthesis. Thus, combined treatment with BEZ235 may 
represent suitable therapy to counteract primary and acquired resistance to RAD001 
in PETs.
INTRODUCTION
Pancreatic endocrine tumors (PETs) are rare 
neoplasms that represent 1-2% of all pancreatic cancers 
[1,2]. They are heterogeneous in terms of clinical 
presentation, histological features, tumor grading and 
staging at time of diagnosis [3,4]. Despite PETs are 
considered to have an “indolent” behaviour, most 
patients display metastases at the time of diagnosis, being 
not eligible for surgery [3]. Furthermore, as PETs are 
characterised by a low proliferation rate, chemotherapy 
is chosen as first line treatment only for a subgroup 
of patients with more aggressive features, whereas 
treatment of the majority of PETs has generally employed 
somatostatin analogues [4]. Nevertheless, these therapeutic 
approaches offer limited clinical benefits for patients.
In the past few years, this therapeutic scenario has 
dramatically changed. Two novel targeted therapies, with 
the selective inhibitor for the serine-threonine kinase 
mTOR (Everolimus or RAD001) and the multi-target 
tyrosine-kinase inhibitor sunitinib, have been approved for 
advanced progressive pancreatic neuroendocrine tumors 
(pNETs) [5,6]. In particular, the rationale for the use of 
RAD001 in PETs is sustained by solid preclinical data 
with human samples and in vitro models that highlighted 
the relevance of the PI3K-mTOR pathway in PETs [7-10]. 
For instance, low expression levels of negative regulators 
of mTOR, such as PTEN and the TSC1/2 complex, are 
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associated with worse prognosis in PET patients [7]. 
Moreover, a number of studies have confirmed the efficacy 
of RAD001 in models of neuroendocrine tumours in vitro 
[11,12]. However, despite the strong rationale and the 
specific mechanism of action of RAD001, not all patients 
respond to the treatment. Indeed, one third of patients 
display primary insensitivity [13], whereas others initially 
experience disease stabilization but they eventually 
develop resistance to the drug and undergo disease 
progression [5].
The PI3K/AKT/mTOR axis is involved in the 
regulation of cell survival, proliferation and motility 
[14]. mTOR is assembled in two main complexes named 
mTORC1, which regulates mRNA translation and protein 
synthesis in response to nutrients [15], and mTORC2, 
which is mainly involved in cytoskeleton remodelling and 
cell survival [16]. Notably, RAD001 specifically targets 
the mTORC1 complex whereas mTORC2 is insensitive 
to it, thus leaving some mTOR functions unaltered upon 
treatment [15,16]. Importantly, mTORC1 participates to 
a negative feedback that keeps the activity of PI3K under 
tight control [17]. As a consequence, mTORC1 inhibition 
can lead to activation of PI3K and of the pro-survival 
kinase AKT [18]. Thus, novel therapeutic strategies that 
avoid instauration of feedback activation of the PI3K/AKT 
axis might be beneficial in long-term treatments of PET 
patients with mTORC1 inhibitors. 
In this work, we aimed at evaluating the response 
of PET cell lines to three novel PI3K inhibitors, the 
dual PI3K-mTOR inhibitor BEZ235 [19], the pan-PI3K 
inhibitor BKM120 [20] and the PI3Kα inhibitor BYL719 
[21]. BEZ235 was the most efficient among the PI3K 
inhibitors in limiting PET cell growth. Notably, although 
BEZ235 alone did not provide an advantage with respect 
to RAD001, combined treatment with these inhibitors 
could overcome the resistance of PET cells to RAD001 
and it significantly lowered the dose required to exert anti-
proliferative effects. The synergic effect relied on more 
efficient inhibition of 4EBP1 phosphorylation, consequent 
impairment of the assembly of the translation initiation 
complex eIF4F and strong inhibition of protein synthesis. 
Thus, our results demonstrate in vitro the efficacy of 
combined treatment with RAD001 and BEZ235 in PET 
cells, providing the basis for studies using in vivo models 
of PET.
RESULTS
Establishment of a PET cell model of acquired 
resistance to RAD001
Clinical data indicate that a subset of PET patients 
respond to RAD001 treatment with tumor regression or 
stabilization, whereas others display primary resistance. 
In addition, the majority of patients that initially respond 
to the treatment then develop secondary resistance 
within 1 year [13]. We aimed at developing cell models 
representing these clinical situations to test the effect 
of three novel PI3K inhibitors in PETs. The PET cell 
lines BON-1 and QGP-1 exhibit a different sensitivity 
to RAD001 in terms of proliferation, with BON-1 cells 
being highly sensitive to the inhibitor and QGP-1 rather 
resistant [7,10]. To determine whether RAD001-sensitive 
cells could acquire resistance to the drug, we treated BON-
1 cells with RAD001 for 8 consecutive weeks. RAD001 
(10 nM) was supplied every 48 hours together with fresh 
medium (Figure 1A). Treatment with RAD001 almost 
completely blocked proliferation of BON-1 cells in the 
first week (Supplementary Figure 1A). However, after 
10-15 days of treatment cells started to grow slowly and 
by the end of the treatment they exhibited a proliferation 
rate in the presence of RAD001 that was comparable to 
that of parental BON-1 cells in the absence of the drug 
(Supplementary Figure 1B). These cells, which we 
named BON-1 RR (RAD001 Resistant) for their acquired 
phenotype, displayed a more elongated shape and fewer 
cell-cell contacts with respect to the morphology of 
parental cells (Figure 1A). Although changes in elongated 
shape are often a hallmark of epithelial-to-mesenchymal 
transition in cancer cells, as exemplified by the MCF-7 and 
MDA-MB-231 breast cancer cells (Figure 1B), we found 
that this is not the case for BON-1 cells. Indeed, parental 
BON-1 cells express mixed markers of both epithelial and 
mesenchymal phenotype and their expression levels are 
not significantly changed in BON-1 RR cells (Figure 1B). 
To validate the differential sensitivity of PET 
cell lines to RAD001, we performed colony formation 
assays, which measure the ability of cells seeded at clonal 
dilutions to form new colonies [22]. As expected, parental 
BON-1 cells were highly sensitive to RAD001, with 
approximately 75-90% inhibition of colony formation at 
1-10 nM concentrations (Figure 1C). QGP-1 cells were 
substantially resistant to the drug, which caused a 20-35% 
reduction in number of colonies (Figure 1C). Strikingly, 
BON-1 RR cells were strongly resistant to RAD001, 
with approximately 10% reduction in colony formation at 
the highest dose (Figure 1C). These results suggest that 
PET cells that are sensitive to mTORC1 inhibition can 
develop resistance to RAD001 treatment, similarly to what 
observed in patients [5,13]. 
PI3K inhibitors display different efficacy in the 
inhibition of PET cell growth. 
In various cancer cell lines, inhibition of mTORC1 
activity causes a feedback activation of PI3K and 
phosphorylation of AKT, resulting in a pro-survival 
response [18]. To test whether such feedback control is 
also active in PET cells, we treated BON-1 and QGP1 
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cells with different doses of RAD001. Notably, RAD001 
induced sustained (4-24 hours) phosphorylation of AKT in 
Thr 308 and Ser 473 in both PET cell lines (Supplementary 
Figure 2). These results suggest that the prosurvival PI3K/
AKT pathway is activated in both RAD001-sensitive and 
-resistant PET cells. 
BEZ235 is a dual inhibitor that inhibits the catalytic 
activity of mTOR and of all class I PI3K isoforms by 
targeting their ATP binding site [19]. BKM120 acts on all 
class I PI3K isoforms [20], whereas BYL719 specifically 
inhibits the activity of the p110α catalytic isoform [21]. 
To evaluate the activity of these compounds in PET cells, 
we initially tested the minimal dose of each drug required 
to inhibit AKT phosphorylation and mTORC1 activity 
in BON-1 and QGP-1 cells (Supplementary Figure 3). 
Phosphorylation of AKT in Thr 308, which is mediated 
by PDK1, was evaluated as marker of PI3K activity, 
phosphorylation of AKT in Ser 473 was evaluated as 
target of mTORC2 activity, whereas phosphorylation of 
rpS6 and of 4EBP1 were evaluated as downstream targets 
of mTORC1 (see Figure 2A for pathway representation).
In both cell lines, BEZ235 inhibited mTORC1 
activity at 10 nM, as indicated by reduced phosphorylation 
of rpS6 and the shift to faster electrophoretic mobility of 
4EBP1 (α isoform in Figure 2B). However, at 100-250 nM 
BEZ235 also impaired PI3K and mTORC2 activities, as 
shown by reduced phosphorylation of AKT in Thr 308 and 
Ser 473, respectively (Figure 2B). By contrast, the other 
two drugs were less effective in inhibiting these pathways 
and required much higher dosage (Supplementary Figure 
3A,B). BKM120 inhibited PI3K (AKT Ser308) and 
partially mTORC1/2 activities at 250-500 nM, whereas 
BYL719 was active at concentrations in the micromolar 
range (1-10 µM) (Figure 2B and Supplementary Figure 
3A,B). Specific inhibition of mTORC1 activity by 
BEZ235 was also tested by monitoring phosphorylation 
of mTOR in Ser 2448, a substrate of the ribosomal S6 
kinase (23) that is activated by the mTORC1 complex 
(15). As expected, we found that increasing doses of 
BEZ235 reduced mTOR phosphorylation, whereas the 
PI3K-specific inhibitors were ineffective (BKM120) or 
exerted a partial effect only at high doses in the RAD001-
sensitive BON-1 cells 10 µM BYL719) (Supplementary 
Figure 3C,D). 
Figure 1: Chronic treatment selects RAD001-resistant BON-1 cells. (A) Scheme of the protocol used to select a RAD001-
Resistant BON-1 cell line (BON-1 RR). Representative images of parental and RAD001-resistant BON-1 cells. BON-1-RR show a more 
elongated shape and fewer cell-cell contacts with respect to the morphology of parental cell (40X magnification). (B) RT-PCR analysis of 
the expression of mesenchymal and epithelial genes in BON-1 and BON-1 RR cells. MCF-7 and MDA-MB-231 breast cancer cells were 
used as positive control of epithelial and mesenchymal phenotype, respectively. (C) Representative images of colony formation assay 
performed with BON-1, QGP-1 and BON-1 RR treated with 1 or 10 nM RAD001. Histograms represent the percentage of inhibition of 
colony formation in comparison to control cells from three experiments (mean ± s.d.). Statistical analysis was performed by the paired 
Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01.
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In order to evaluate the effect of the PI3K inhibitors 
on PET cell proliferation and survival, we performed 
colony formation assays. In BON-1 cells, BEZ235 did 
not confer an advantage with respect to RAD001 and 
suppressed colony formation at 3-10 nM concentration 
(Figure 2C), a dose at which this inhibitor affected 
mTORC1 activity but not PI3K activity (Figure 2B). 
By contrast, in QGP-1 cells, which are rather resistant 
to RAD001 and to doses of BEZ235 that inhibit only 
mTORC1, increasing doses of BEZ235 significantly 
inhibited colony formation and growth with respect to the 
effect of RAD001 (Figure 2C). This result might indicate 
that inhibition of PI3K activity overcomes RAD001 
resistance in PET cell lines. However, BKM120 and 
Figure 2: PI3K inhibitors display different efficacy in the inhibition of PET cell growth. (A) Schematic representation of 
the PI3K/Akt/mTOR pathway. (B) Western blot analysis of 4EBP1, p- AKT Ser 473, p-AKT Thr 308, p-rpS6 Ser 240-244 and p-rpS6 Ser 
235-236 in BON-1 and QGP-1 treated with the PI3K inhibitors BEZ235, BKM120 and BYL719 for 4 hours. Actin was used as loading 
control. (C) Colony formation assays performed in BON-1 and QGP-1 treated with the PI3K inhibitors and RAD001. Histograms show the 
percentage of inhibition of colony formation in comparison to control cells from three experiments (mean ± s.d.). Statistical analysis was 
performed by the paired Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01.
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BYL719 did not suppress QGP-1 colony formation even at 
doses that efficiently inhibited PI3K activity, whereas they 
were more efficacious in BON-1 cells (Figure 2C). Thus, 
these observations suggest that the concomitant inhibition 
of mTORC1 and PI3K/mTORC2 exerted by high doses of 
BEZ235 is beneficial to limit growth of RAD001-resistant 
PET cells.
Combined treatment with BEZ235 and RAD001 
overcomes resistance of PET cells to RAD001
To test whether combined treatment with BEZ235 
and RAD001 provides an advantage with respect to 
single treatment with each drug, we evaluated their effect 
in PET cells that are resistant to RAD001 alone (QGP-
1 and BON-1 RR cells) by colony formation assays. 
As shown above (Figure 2C), QGP-1 cells were rather 
resistant to BEZ235 at concentrations (1-10 nM) that 
selectively inhibited mTORC1, whereas their growth 
was strongly inhibited at concentrations (100-250 nM) 
that also suppress PI3K and mTORC2 activity (Figure 
3A). A similar result was observed for BON-1-RR cells 
(Figure 3B). However, when low doses of BEZ235 (1-
10 nM) were administered in combination with 1 nM 
RAD001, growth was significantly inhibited in both 
QGP-1 (~25-65% inhibition, Figure 3A) and BON-1-
RR (~50-80% inhibition, Figure 3B) cells. Importantly, 
increasing the dose of RAD001 to 10 nM did not provide 
a significant amelioration of the effect of BEZ235 (Figure 
3A,B). Direct measurement of cell proliferation and 
cell death indicated that the combined treatment mainly 
affected proliferation of PET cells (Supplementary Figure 
4A,B). Notably, co-treatment of cells with RAD001 
and BKM120, which inhibits only PI3K, did not exert a 
synergic effect on PET cell proliferation (Supplementary 
Figure 5). These data indicate that combined treatment of 
PET cells with RAD001 and BEZ235 is more effective 
with respect to the action of each drug alone. Furthermore, 
the combined treatment allows lowering tenfold the 
minimal concentration of both drugs required to exert 
significant inhibition of PET cell growth. 
Combined treatment with BEZ235 and RAD001 
efficiently suppresses phosphorylation of AKT 
and 4EBP1 in RAD001-resistant PET cells
To investigate the molecular mechanism(s) 
underlying the synergic effect of BEZ235 and RAD001 in 
PET cells, we performed Western blot analyses of relevant 
targets of the PI3K and mTORC1 pathway. We found 
that in both QGP-1 (Figure 4A) and BON-1 RR (Figure 
4B), treatment with 10 nM RAD001 or 10 nM BEZ235 
alone did not completely block mTORC1 activity, as 
indicated by the substantial amount of high molecular 
weight forms (β and γ isoforms) of its direct substrate 
4EBP1. In addition, under these conditions AKT remained 
Figure 3: Combined treatment with BEZ235 and RAD001 overcomes resistance of PET cells to RAD001. Colony assay 
performed in QGP-1 (A) and BON1-RR (B) treated with BEZ235, RAD001 or both inhibitors as indicated. Histograms show the percentage 
of inhibition of colony formation in comparison to control cells from three experiments (mean ± s.d.). Statistical analysis was performed 
by the paired Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01.
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phosphorylated in Thr 308 and Ser 473. By contrast, 
when RAD001 and BEZ235 were administered together 
(10 nM each), 4EBP1 phosphorylation was completely 
suppressed, whereas AKT phosphorylation was attenuated 
in QGP-1 cells (Figure 4A) and abolished in BON-1-RR 
cells (Figure 4B). Similarly to what observed with the 
colony formation assay, concomitant inhibition of PI3K/
mTORC2 and mTORC1 pathways could be obtained by 
raising the concentration of BEZ235 alone to 100 nM. 
These results suggest that the synergism between RAD001 
and BEZ235 is due to more efficient inhibition of both the 
PI3K/mTORC2 and the mTORC1 pathways elicited by the 
combined treatment (see Discussion). 
Combined treatment with BEZ235 and RAD001 is 
required to inhibit protein synthesis in RAD001-
resistant PET cells
A key function of the mTORC1 complex is the 
regulation of mRNA translation initiation complex [24]. 
Phosphorylation of 4EBP1 by mTORC1 inhibits its 
interaction with the eukaryotic initiation factor eIF4E. 
This allows recruitment of the scaffold protein eIF4G 
and the RNA helicase eIF4A by eIF4E to form the active 
eIF4F translation initiation complex at the 5’-cap of 
mRNAs and triggers translation initiation [24]. To test 
whether combined treatment with RAD001 and BEZ235 
affected translation initiation, we performed 5’-methyl-
cap assays to pull down eIF4E and its associated proteins 
[25]. In the absence of treatment, eIF4E was associated 
with substantial amount of eIF4G and eIF4A in both 
QGP-1 (Figure 5A, right panel) and BON-1-RR (Figure 
5B, right panel) cells, indicating efficient assembly 
of eIF4F. Treatment with RAD001 or BEZ235 alone 
did not significantly reduce eIF4F formation, even 
though a partial de-phosphorylation of 4EBP1 was 
observed in the cell extracts (Figure 5A,B, left panels). 
By contrast, concomitant treatment with RAD001 and 
BEZ235 completely suppressed 4EBP1 phosphorylation 
and promoted its strong association with eIF4E and 
disassembly of eIF4F, as demonstrated by the strong 
reduction in eIF4G and eIF4A bound to eIF4E (Figure 
5A,B). 
The results illustrated above suggest that the effect 
of combined treatment with RAD001 and BEZ235 on PET 
cell growth correlates with the inhibition of translation 
initiation and consequent reduction in protein synthesis. 
To directly test this hypothesis, we performed metabolic 
labelling of PET cells with a mix containing 35S-labeled 
aminoacids to measure the effect of RAD001 and BEZ235 
on protein synthesis. We found that RAD001 or BEZ235 
alone had mild (QGP-1 cells, Figure 5C) or no effect 
(BON-1 RR cells, Figure 5D) on protein synthesis. By 
contrast, when the two inhibitors were administered in 
combination, protein synthesis was strongly reduced in 
both QGP-1 cells (70%, Figure 5C) and BON-1 RR cells 
(55%, Figure 5D), confirming the results on the effect on 
eIF4F assembly. Notably, although in QGP-1 cells each 
inhibitor could slightly reduce protein synthesis, combined 
treatment exerted a significantly stronger effect than each 
single agent (brackets in Figure 5C), similarly to what 
observed on cell growth and eIF4F assembly. 
Collectively, these observations strongly indicate 
that combined treatment with RAD001 and BEZ235 exerts 
a synergic effect on PET cell growth through enhanced 
inhibition of the PI3K/AKT/mTOR axis, impairment of 
eIF4F complex assembly and consequent reduction of 
protein synthesis. 
DISCUSSION
Everolimus (RAD001) is currently employed as first 
line agent for advanced, progressive PETs [5,13,26,27]. 
The molecular target of RAD001 is the PI3K/AKT/
mTORC1 axis, which is often deregulated in PET patients 
[13,26] and in other types of human cancers [24,28]. 
Figure 4: Combined treatment with BEZ235 and 
RAD001 efficiently suppresses phosphorylation of 
AKT and 4EBP1 in RAD001-resistant PET cells. 
4EBP1, p-AKT Ser 473, p-AKT Thr 308, p-rpS6 Ser 240-244 
and p-rpS6 Ser 235-236 in QGP-1 (A) and BON-1 RR (B) 
treated with the BEZ235 (indicated dose), RAD001 (10 nM) or 
both inhibitors. Actin was used as loading control.
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Unfortunately, however, a relevant number of PET patients 
show a primary resistance to treatment with RAD001 or 
acquire a secondary resistance after chronic exposure 
[13,26]. Furthermore, clinical trials have demonstrated 
that RAD001 delays but does not block PET progression 
[27]. PET cell models showing sensitivity to RAD001 
(BON-1) or primary resistance to the drug (QGP-1) have 
been already described [7,10]. Herein, we have established 
a new PET cell model for the study of acquired resistance 
to RAD001. BON-1 cells were exposed to the drug 
chronically for 8 weeks, until their growth rate became 
similar to that of parental cells in the absence of RAD001 
(BON-1-RR cells). Direct examination of the sensitivity 
of BON-1 RR to RAD001 confirmed their increased 
resistance to mTORC1 inhibition. Thus, we employed 
BON-1, QGP-1 and BON-1-RR cells as in vitro models 
of the clinical cases of PET patients to test the efficacy of 
drugs that target the PI3K/AKT/mTORC1 axis at different 
levels.
RAD001 is a synthetic analogue (rapalog) of 
rapamycin, which functions as an allosteric inhibitor of 
the mTORC1 complex [29]. The sensitivity to rapalogs 
has been associated to low eIF4E/4EBP1 ratios, whereas 
increased eIF4E expression and/or decreased 4EBP1 
expression confer resistance in cancer cells [30]. However, 
we found that the eIF4E/4EBP1 ratio was not significantly 
different in RAD001-sensitive (BON-1) and insensitive 
(QGP-1 and BON-1 RR) PET cells (Supplementary Figure 
6), suggesting that another mechanism is involved. 
Adaptation of cancer cells to chronic treatment with 
rapalogs has been attributed to feedback activation of the 
PI3K/AKT pathway and to the consequent induction of 
prosurvival responses in cancer cells [17,30]. Moreover, 
for unknown reasons rapalogs efficiently block mTORC1-
dependent S6 kinase activation but poorly suppress 
mTORC1-dependent phosphorylation of 4EBPs [30]. This 
weakness can be, however, overcome by new generation 
mTOR inhibitors that directly target the catalytic activity 
of the kinase [31,32]. Herein, we aimed at determining 
whether inhibition of PI3K activity could be beneficial to 
counteract growth of PET cell lines that are, or become, 
resistant to rapalogs. Among the inhibitors tested, BEZ235 
resulted the most efficient in terms of inhibition of the 
PI3K/AKT/mTORC1 pathway and cell proliferation. 
Interestingly, BEZ235 is a dual inhibitor that targets the 
catalytic activity of PI3K, mTORC1 and mTORC2 [19]. 
However, we found that BEZ235 apparently inhibits these 
kinases at different concentrations in PET cells, with 
mTORC1 activity being suppressed at 1-10 nM while 
higher doses (100-250 nM) were required to inhibit PI3K 
and mTORC2. Notably, BON-1 RR and QGP-1, which 
show resistance to RAD001, do not respond to BEZ235 
at doses that impair solely mTORC1 activity, but are 
sensitive to higher doses at which PI3K and mTORC2 
Figure 5: Combined treatment with BEZ235 and RAD001 efficiently suppress assembly of the translation initiation 
complex eIF4F and protein synthesis in RAD001-resistant PET cells. 7-methyl-GTP Sepharose Assay in QGP-1 (A) and 
BON-1 RR (B) treated with RAD001 (10 nM), BEZ235 (10 nM) or both inhibitors (10 nM each). The proteins absorbed to 7-methyl-GTP-
Sepharose beads were analyzed in Western blot with antibody for eIF4G, eIF4A and 4EBP1. (C-D) Protein synthesis was measured by 
35S-aminoacids incorporation in QGP-1 (C) and BON-1 (D) cell lines. Cells were treated for 72 hours with inhibitors as indicated in the 
legend. The inhibitors were supplied at T=0 hours and at T= 36 hours together with fresh medium. 35S-aminoacid mix was added in the last 
30 min of the culture. Results of 35S-aminoacid incorporation are expressed as mean ± s.d. of three experiments. Statistical analysis was 
performed by the paired Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01.
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are also blocked. Inhibition of PI3K activity per se does 
not explain the sensitivity of PET cells to high doses of 
BEZ235, as the other two PI3K inhibitors tested (BKM120 
and BYL719) had marginal effects on cell growth despite 
their ability to suppress PI3K-dependent phosphorylation 
of AKT. Thus, the higher activity of BEZ235 resides in its 
ability to concomitantly suppress PI3K and mTOR activity 
at higher doses.
The clinical use of BEZ235 is currently being 
evaluated in a variety of solid tumors [33]. A limitation 
to its employment at high doses might potentially be 
represented by development of toxicity. On the other 
hand, the clinical limitation of RAD001 is represented 
by development of resistance in patients [13,26,27]. To 
determine whether a combined treatment with RAD001 
and BEZ235 could circumvent these problems, we 
exposed PET cells to both drugs. Our study revealed 
two important findings. First, we found that co-treatment 
with the two drugs exerted a synergic effect on PET cell 
proliferation, with up to 80% inhibition obtained with 
doses of each compound that caused marginal effects when 
supplied alone. Moreover, we found that the synergic 
effect of BEZ235 was elicited at doses that efficiently 
inhibited mTORC1 but not PI3K activity. This effect 
might be due to the different nature of mTOR inhibition 
by RAD001 and BEZ235, with the former acting 
allosterically by binding to FKB12 and the latter directly 
on the catalytic activity of the kinase [32]. It should also 
be reminded that although at the 10 nM concentration 
BEZ235 appears to selectively block mTORC1 in PET 
cells, recent evidence suggest that extensive crosstalk 
between the mTORC1 and mTORC2 complexes exist [34] 
and may enhance the effect of this drug in vivo. Moreover, 
since 10 nM overcomes the IC50 of BEZ235 on PI3Ks 
(19), it is also possible that, although we do not detect 
an inhibition of AKT phosphorylation, PI3K activity 
might be partially inhibited and this could affect PET cell 
proliferation. Another possibility is that BEZ235 exerts its 
synergic effect by inhibiting another kinase beside PI3K 
and mTOR. However, although we cannot completely 
rule out this possibility, it remains unlikely, as in vitro 
studies demonstrated an extreme specificity of BEZ235, 
with all other kinases tested being inhibited at doses much 
higher than dose employed in our study [19]. Thus, our 
results suggest that targeting the mTORC1 complex with 
allosteric and catalytic inhibitors synergistically impairs 
PET cell proliferation. In this regard, BEZ235 may 
present several advantages with respect to other catalytic 
inhibitors of mTOR [30,35], because the clinical use of 
BEZ235 is already in a more advanced stage (see below) 
and this drug can concomitantly inhibit the PI3K pathway, 
thus possibly reinforcing growth inhibition.
Previous studies in other cancer cell types indicated 
that limited or absent inhibition of phosphorylation of 
4EBPs was the main cause of resistance to rapalogs and 
that this resistance could be eliminated by new generation 
inhibitors targeting the kinase activity of mTOR [30,35]. 
However, our results indicate that combined treatment with 
RAD001 and BEZ235 results in much stronger growth 
inhibition than either drug alone in PET cells, suggesting 
that the effect is not simply due to stronger efficacy of 
catalytic inhibitors with respect to rapalogs. Other studies 
also suggest that combined treatment with RAD001 and 
BEZ235 may exert a synergic effect on cell survival and 
proliferation in other cancer types [36,37], although the 
mechanism underlying this effect was not addressed. Here, 
we found that the anti-proliferative effect of the combined 
therapy directly correlates with the ability to suppress 
4EBP1 phosphorylation and to interfere with the assembly 
of the translation initiation complex in PET cells. Indeed, 
our data show that RAD001 and BEZ235 used as single 
agents only partially reduced phosphorylation of 4EBP1 
and interaction of eIF4E with eIF4G and eIF4A, whereas 
they abolished 4EBP1 phosphorylation and eIF4F 
assembly when administered together. This effect is 
biologically relevant, as it was reflected in a much stronger 
inhibition of protein synthesis in BON-1 RR and QGP-1 
cells with respect to cells treated with RAD001 or BEZ235 
alone. Thus, concomitant allosteric and catalytic inhibition 
of mTORC1 is necessary to efficiently circumvent primary 
and secondary resistance to RAD001 in PET cell lines. 
BEZ235 is currently under evaluation in a clinical 
trial that investigates its use in patients with advanced 
PETs after failure of RAD001 (ClinicalTrials.gov 
Identifier:NCT01658436). In this regard, we found that 
BEZ235 had minor effects on RAD001-resistant PET 
cells at doses at which it completely suppressed mTORC1-
dependent S6K activity. This result suggests that acquired 
resistance to rapalogs in PET cells cannot be overcome 
by treatment with catalytic inhibitors of mTORC1. By 
contrast, increasing the dose of BEZ235 to 100 nM, at 
which PI3K and mTORC2 activities are also inhibited, 
strongly suppressed PET cell growth. Thus, BEZ235 
might be beneficial as second line agent but it is likely 
that the high dosage required for cell growth inhibition 
will cause unwanted responses in patients. Nevertheless, 
our findings suggest that addition of low doses of 
RAD001 may strongly sensitize PET cells to BEZ235 
and potentially limit the onset of adverse responses in 
patients, as the combined therapy reduced the dose of each 
drug required to obtain efficient tumor growth inhibition 
in vitro. Notably, such strategy is under evaluation in 
different solid tumors [33], but not in PETs to the best of 
our knowledge. 
In conclusion, our study suggests that combined 
therapy with RAD001 and BEZ235 might be particularly 
beneficial to patients that become insensitive to RAD001 
treatment and provide the basis to test this hypothesis in a 
preclinical model of PET in vivo. 
Oncotarget5389www.impactjournals.com/oncotarget
MATERIAL AND METHODS
Inhibitors
RAD001 and the PI3K inhibitors (BEZ235, 
BKM120 and BYL719) were generously provided by 
Novartis Oncology (Basel, Swiss). Inhibitors were 
dissolved in dymethil sulfoxide (DMSO, Sigma- Aldrich), 
and the stock solutions were diluted to final concentrations 
in medium.
Cell cultures, treatments and extracts preparation
BON-1 and QGP-1 cells were cultured as previously 
described [10,38]. BON-1 RR (RAD001-Resistant) cells 
were obtained after chronic treatment with RAD001 for 
eight weeks. During treatment, 10 nM RAD001 was added 
to the cell culture every 48 hours. 
For western blot analysis, cells were seeded at 
70% of confluence. After 24h medium was changed and 
inhibitors was added to the cultures. After incubation, 
cells were washed with ice-cold phosphate buffered 
saline (PBS) and resuspended in lysis buffer (100mM 
NaCl, 15mM MgCl2, 30mM Tris-HCl pH 7.5, 1mM 
dithiothreitol, 2mM Na-ortovanadate, Protease-Inhibitor 
Cocktail (Sigma-Aldrich) and 1% Triton X-100). Cells 
were incubated on ice for 10 minutes and protein extracts 
were separated by centrifugation at 12000g, resuspended 
in SDS-page sample buffer and boiled for 5 minutes 
before using them for SDS-PAGE analysis. 
RT-PCR Analysis
Total RNA was extracted from cells using Trizol 
reagent (Invitrogen) according to the manufacturer’s 
instructions and 1μg was used for retrotranscribed (RT) 
using M-MLV reverse transcriptase (Invitrogen). Five 
percent of the RT reaction was used as template for PCR 
analysis (GoTaq, Promega). The sequences of all primers 
used are listed in Supplemental Table 1. 
SDS- PAGE and Western blot analyses
Protein extracts were separated by SDS-PAGE and 
analysed by Western blot as previously described [38]. 
The primary antibodies used are: rabbit anti-actin (1:1000, 
Sigma-Aldrich); rabbit anti-4E-BP1 (1:1000), rabbit 
anti-4EBP1 pSer65 (1:500), rabbit anti-eIF4E (1:1000), 
rabbit anti-eIF4G (1:1000), rabbit anti-AKT pThr308 
(1:200), rabbit anti-rpS6 pSer240-244 (1:1000), rabbit 
anti-rpS6 pSer235-236 (1:1000) (all from Cell Signalling 
Technology); rabbit anti-pSer473 AKT (1:1000) (from 
BioSource); rabbit anti-eIF4A (1:1000) (Abcam). Actin 
was used as loading control to normalize the samples. 
Secondary IgGs conjugated with horseradish peroxidise 
(1:10 000; Amersham Bioscience) were incubated 
for 1 hour and signals were detected by enhanced 
chemioluminescence (Santa Cruz Biotechnology).
Colony Formation Assay
Single-cell suspensions were plated in 35mm plates 
at low density (1000 cells/plate) [22]. After 1 day, cells 
were treated with inhibitors as indicated in the figures. 
The medium was changed every 48 hours and inhibitors 
were added at every change of medium. After 10 days, 
cells were fixed in methanol for 10 minutes and stained 
overnight with 5% Giemsa. Plates were then washed twice 
with PBS and dried. Pictures were acquired using digital 
camera to count the colonies. Results represent the mean 
± s.d. of three experiments.
Cell Count and viability Assay
Cell count was used to monitor cell proliferation. 
BON-1 RR and QGP-1 were seeded at 40000 cells/plate in 
24-well plates and treated for 72 hours as described. At the 
end of treatments, cells were washed in PBS, trypsinized 
and counted using the Thoma’s chamber.
For apoptosis assays, cells were seeded at 80 000 
cells/plate in 12-well plates and treated with inhibitors 
as indicated. Cells were fixed for 10 minutes in 4% 
paraforlmaldeyde (PFA) and permeabilized with 0,1% 
Triton X-100 for 10 minutes. After 1 hour with PBS 
with 3% BSA, cells processed for immunofluorescence 
analysis using the anti-cleaved caspase-3 antibody (1:400 
dilution, Sigma-Aldrich) for 1 hour and 30 minutes. 
Cells were incubated with secondary antibody (1:500 
dilution; Jackson ImmunoResearch Laboratories). Five 
random fields were chosen and at least 100 cells/field 
were counted. Results represent the mean ± s.d. of three 
experiment performed in triplicate.
7-Methyl-GTP-Sepharose Chromatography
Assembly of eIF4F complex was evaluated 
essentially as previously described [10,25]. Briefly, 
PET cells were resuspended in lysis buffer (see above) 
containing 0,5% Triton X-100 and 30 U/mL RNasin 
(Promega). Cell extracts were incubated for 10 minutes 
on ice and centrifuged at 12000g for 10 minutes at 4°C. 
The supernatant fractions were pre-precleared for 1 hour 
on Sepharose beads (Sigma-Aldrich) and then centrifuged 
at 1000g for 1 minute. Pre-cleared supernatants were then 
incubated with 7-Methyl-GTP Sepharose (Amersham 
Bioscience) for 90 minutes at 4 °C under constant shaking. 
After three washes in lysis buffer, bound protein were 
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eluted in SDS-PAGE sample buffer and analysed by 
Western blot
Protein Synthesis Assay. 
For the measurement of protein synthesis rate, 2x105 
cells were plated in 35 mm dishes in presence of inhibitors 
as indicated. In the last 30 minutes [35S]-cell labelling mix 
(Perkin Elmer EasyTag ™ Express35S35S, 1000 Ci/nmol) 
was added to final concentration of 10 ɥCi/mL. Cells were 
lysed in High Salt Buffer (HSB) (Tris HCl pH 7.5 50 mM, 
NaCl 350 mM, MgCl2 1 mM, EDTA 0,5 mM, EGTA 0,1 
mM) with 1% NP-40) and proteins were precipitated in 
10% trichloroacetic acid. After three washes with 5% 
cold thricloroacetic acid, the insoluble materials was 
collected on GFC filters (Whatman) and the incorporated 
radioactivity was measured in scintillation fluid. Results 
represent mean ± s.d. of three experiments.
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Supplementary Figure 1: Effect of RAD001 on cell proliferation in BON-1 and BON-
RR. (A) Proliferation of BON-1 was assayed by MTS assay after 72 hours in presence of 
different doses of RAD001, as indicated. (B) The graph represents the cell count of BON-1 
(without RAD001) and BON-1 RR (in presence of 10 nM RAD001) at different times, as 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Figure 2: RAD001 treatment induces phosphorylation of AKT in PET 
cell lines. Western Blot analysis of p-AKT in Thr 308 and Ser 473, p-rpS6 in Ser 235-235 and 
Ser 240-244, and 4EBP1 during treatment with different doses of RAD001 in BON-1 (A) and 
QGP-1 (B). 
 
 
 
 
 
 
Supplementary Figure 3: Effect of PI3K inhibitors on the PI3K/AKT/mTOR pathway in 
PET cell lines. Western Blot analysis of p-AKT Thr 308 and p-rpS6 Ser 240-244 in BON-1 (A) 
and QGP-1 (B) and of mTOR, p-mTOR Ser 2448 and p-rpS6 Ser 240-244 in BON-1 (C) and 
QGP-1 (D) cells. PET cells were treated for 4 hours with increasing doses of PI3K inhibitors as 
indicated in the figure. 
 
 
 
 Supplementary Figure 4: Combined treatment with BEZ235 and RAD001 exerts a 
synergic effect on cell proliferation. (A) Cell proliferation was assayed by cell count after 72 
hours in QGP-1 and BON-1 RR cells treated with BEZ235, RAD001 or both inhibitors as 
indicated. Histograms show the percentage of inhibition of number of cells in comparison to 
control cells from three experiments (mean ± s.d.). (B) Cell death was detected by 
immunofluorescence analysis of the cleaved form of caspase-3 after 72 hours in QGP-1 and 
BON-1 RR cells treated with Cisplatin, BEZ235, RAD001 or both inhibitors as indicated. 
Histograms show the percentage of cleaved caspase-3 positive cells from three experiments 
(mean ± s.d.). Statistical analysis was performed by the paired Student’s t-test; * P ≤ 0.05, ** P 
≤ 0.01. 
 
 
 
 
 
 
  
 
 
 
 
Supplementary Figure 5: Combined treatment with BKM120 and RAD001 does not exert 
a synergic effect on cell proliferation and cell viability. Cell proliferation was assayed by cell 
count after 72 hours in QGP-1 and BON-1 RR treated with BKM120, RAD001 or both 
inhibitors as indicated. Histograms show the percentage of inhibition of number of cells in 
comparison to control cells from three experiments (mean ± s.d.).Statistical analysis was 
performed by the paired Student’s t-test; 
* 
P ≤ 0.05, 
** 
P ≤ 0.01. 
 
 
 
 
 
 
 
 
 
 Supplementary Figure 6: RAD001-sensitive and insensitive PET cells display similar 
eIF4E/4EBP1 ratios. (A) Representative image of Western Blot analysis of eIF4E, 4EBP1 and 
Actin in PET cell lines. Actin and Coomassie Staining were used as loading control. (B) 
Densitometric analysis of eIF4E and 4EBP1, after each was normalized with respect to Actin 
levels. Results are the mean + standard deviation of three independent experiments. 
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CHAPTER IV 
 
Pancreatic Ductal Adenocarcinoma (PDAC) 
 
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and 
lethal solid tumors, characterized by a 5 years survival-rate of 6% and of an incidence 
rate almost equal to the mortality rate (Ferlay et al., 2010). PDAC represents 95% of 
pancreatic tumors, while the rest 5% is represented by endocrine tumors.  
The incidence of PDAC is only 4% of all tumors, although it represents the 
fourth cause of cancer-related death in the western-world (Ferlay et al., 2010; Hariharan 
et al., 2008). The high incidence of mortality for this cancer is due to late diagnosis, 
caused by the absence of symptoms in the early stages of cancer. Moreover, most 
patients present with metastasis at time of diagnosis, and only a small fraction of cases is 
eligible for surgery treatment, which remains the only treatment that prolongs survival. 
Indeed, PDAC is characterized also by poor response to chemotherapy and radiotherapy, 
which determines a low median survival of patients affected by this aggressive disease 
(Cunningham et al., 2009; Stathis and Moore, 2010). These data strongly emphasize the 
urgent need for improvements in diagnosis and treatment of PDAC, which remains, to 
date, incurable. 
 
4.1 Risk factors and symptoms 
Genetic and environmental risk factors were extensively studied for their 
association with PDAC. Among the established risks, advanced age and sex were linked 
to this disease. Indeed, most patients are in advanced age (50-70 years) at time of 
diagnosis, and the disease is more common in man than women, with a ratio between 
two sexes of 1.3/1 (Ferlay et al, 2010). 
Among the risk factors studied for their association to PDAC, the most important 
is smoke, which is associated with PDAC in 20-30% of cases, and it increases the risk of 
insurgence of PDAC by 74%. Moreover, dietary factors are included among risk factors, 
as consumption of red meat and alcohol (with a 20-30% of increased risk of PDAC), 
obesity and presence of diabetes. Other risk factors related to PDAC are also chronic 
infection by HCV and HBV and chronic pancreatitis (Wörmann and Algül, 2013). 
Genetic traits have also been associated with PDAC. Up to 10% of PDAC cases 
show family history and are linked to inherited genetics factors associated with inherited 
syndormes. Among these, PDAC is associated with hereditary cancer syndromes, such 
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as the Peutz–Jeghers syndrome, Familial-atypical multiple melanoma syndrome, Li–
Fraumeni syndrome, Hereditary non-polyposis colorectal cancer, Familial adenomatosis 
polyposis and Ataxia teleangiectasia (Wörmann and Algül, 2013). 
In the early stages of PDAC, most symptoms are not specific of the pathology 
and do not allow an early diagnosis. The most diffused symptoms are abdominal pain, 
weight loss, and jaundice, caused by the infiltration of tumor in the common bile duct. 
Hence, most of PDACs are diagnosed in the late phase of the disease, when symptoms 
are related to local or metastatic spreading of tumor. 
 
4.2 Diagnosis and Staging 
Symptoms of PDAC are often related to aberrant functionality of pancreas and 
liver. For this reason, blood analysis is initially used to detect dysfunctions of these 
organs. If PDAC is suspected, the approach used to detect it is a radiological diagnosis. 
In order to visualize a suspected tumor, Multidetector Computed Tomography (MDCT), 
Magnetic Resonance (MRI) and Endoscopic Ultrasound (EUS) techniques are used. 
During EUS, samples of tissue can be taken in order to allow morphological and 
molecular inspection of the pancreatic lesions. Moreover, MRI and Computed 
Tomography (CT) are employed for the staging of the disease. In this way, the three-
dimensional reconstruction of the neoplasm provides more information about the 
position of tumor with respect to neighbouring vessels, in order to classify tumors as 
surgically resectable. Position Emission Tomography (PET) is also employed to define 
the staging of the disease and to detect distal metastases (Vincent et al., 2011). 
Radiological techniques used for diagnosis provide information required for the 
concomitant staging of PDAC. The TNM classification, which is largely used for 
PDAC, describes tumors for size, presence of lymph nodes invasion, distal metastases 
and the resectability of primary tumor. (Varadhachary et al., 2006). 
On the basis of TNM classification, PDAC is classified in four stages:  
• Stage I: Tumor is localized in pancreas and resectable. 
• Stage II: Tumor is spread locally without invasion of other organs or limph 
nodes, and it is resectable. 
• Stage III: tumor spread to lymph nodes and invaded the pancreatic duct, only a 
fraction of cancers is resectable 
• Stage IV: tumor is spread to distal organs as lungs, liver and colon, and the 
disease at this stage is defined as metastatic. 
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The survival rate related to different stages is variable, albeit survival at five 
years from diagnosis remains extremely low, thus suggesting the need to improve early 
detection of PDAC. 
 
4.3 Treatment 
Treatment of PDAC depends on the stage at time of diagnosis. If the tumor is 
confined to pancreatic tissues, surgical resection is the first line treatment. Furthermore, 
rurgical resection is followed by adjuvant therapy with chemotherapy, recommended in 
patients that choose surgery with curative intent. When patients have a borderline 
resectable disease, chemotherapy is applied in order to reduce the size of the primary 
tumor before surgical resection (neoadjuvant treatment) (Vincent et al., 2011).  
In advanced metastatic disease, chemotherapy is used as a palliative treatment, in 
order to improve the quality of life. The chemotherapeutic drug used for PDAC is 
Gemcitabine, which slightly increases overall survival of patients. Gemcitabine is an 
analogue of cytidine, and during DNA replication is incorporated in neo-replicated 
molecules of DNA (Burris et al., 1997), leading cells exposed to this genotoxic stress to 
the activation of apoptosis. 
Gemcitabine was selected for treatment of PDAC for increased benefits in terms 
of prolongation of life with respect to 5-Fluorouracile (5-FU) (Burris et al., 1997). It is 
currently used in monotherapy or in combination with other drugs. For instance, 
combined treatment with gemcitabine and nab-paclitaxel was shown to increase the 
overall survival compared to gemcitabine alone (Von Hoff et al., 2013). Indeed nab-
paxlitaxel (nanoparticle albumine-bound paxlitaxel), penetrates more efficiency through 
the stroma present around the PDAC lesions, which is thought to represent a physical 
barrier for chemotherapeutic drugs. However, after cycles of gemcitabine treatment, 
patients invariably become unresponsive to chemotherapy, suggesting that PDAC cells 
are able to activate pro-survival pathways and to acquire a resistant phenotype. 
Another chemotherapeutic approach proposed for the treatment of PDAC is 
FOLFIRINOX (5-FU, leucovorin, irinotecan and oxaliplatin), which increases survival 
of patients with PDAC, albeit it does not improve their quality of life due to side effects 
during the therapy (Conroy et al., 2011). 
Despite the novel therapies proposed for the treatment of advanced PDAC, no 
significant results have been obtained in terms of survival. This is due primarily to the 
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the acquisition of chemoresistance, the main feature of the malignancy of PDAC, which 
must be overcome to improve the efficiency of therapies 
 
4.4 Molecular characterization of PDAC 
PDAC arises from neoplastic lesions in ductal cells. Among the lesions, the most 
common are the Pancreatic Intra-epithelial Neoplasia (PanIN) (Hruban et al., 2001), 
which are classified into three groups, based on the grade of dysplasia and 
morphological transformation of the cells: PanIN-1, PanIN-2 and PanIN-3. In PanIN-1, 
ductal cells show a low grade of displasia. This gradually increases until the PanIN-3 
grade, which is defined also as carcinoma in situ. All the PanIN lesions are confined 
within the basement membrane, without invasion of other tissues. With the increase of 
cellular dysplasia, the neoplastic lesions become invasive PDAC. 
The morphological changes of pancreatic ductal cells during tumorigenesis are 
accompanied by defined mutations and genetic alterations (Figure 4.1), which have 
been characterized for the first time through a genetic global analysis of PDAC tumor 
samples (Jones et al., 2008). Mutations in the oncogene KRAS2 was found in 20% of 
PanIN-1, and the percentage of mutation in this gene increases up to 90% in PanIN-3 
(Kanda et al., 2012). Another important gene mutated in early stages of PDAC is in the 
gene encoding the oncosuppressor and cell cycle regulator CDKN2A/p16, which was 
found mutated in 50% of PanIN-1 and in 95% of PDAC patients (Wilentz et al., 1998; 
Otthenof et al., 2011).  
During the progression of PDAC tumorigenesis other important genes, involved 
in several important cellular functions, were found mutated, such as TP53, CCND1, 
BRCA2, SMAD4 , with a concomitantly increase of  Ki-67. Deregulation of these genes 
during the last stages of PanIN promotes the progression of neoplastic lesions to PDAC, 
where the percentage of most of these mutations increases over 50% (Otthenof et al., 
2011). 
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Figure 4.1. Schematic representation of genetic alterations during PanIN progression (Otthenof et al., 
2011). 
 
High-throughput analyses of PDAC samples contributed to a global dissection of 
the pathways deregulated in this disease, inclusing those regulating cell cycle 
progression, apoptosis, DNA damage repair, cell adhesion and invasion and important 
signalling pathways, such as the MAPK and TGFβ ones (Otthenof et al., 2011). A more 
recent study provided an even deeper understanding of genetic alterations in PDAC 
tumors, and illustrated the correlation between mutations and response to therapies 
(Waddel et al., 2015). Importantly, alterations in chromosomal structures were also 
found in PDAC tumors, indicating that also chromosomal rearrangement play an 
important role in PDAC progression (Waddel et al., 2015). 
The recent evidences of genetic alterations in PDAC underline a large 
heterogeneity, which may be the basis of differences in progression and response to 
chemotherapeutic treatment. Thus, it would be important defines the genetic pattern of 
the desease in order to identify a specific therapy for each case of PDAC. 
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CHAPTER V 
 
Role of Epithelial to Mesenchymal Transition (EMT) in 
PDAC 
 
Epithelial to Mesenchymal Transition (EMT) is a physiological process that 
determines morphological changes in epithelial cells, allowing the acquisition of 
fibroblastic-like shape and the ability to lose cell-to-cell contacts and to migrate (Figure 
5.1). EMT is characterised by a profound reprogramming of gene expression, which 
drives transformation of cells from an epithelial phenotype to a mesenchymal one.  
EMT occurs normally during embryonic development and it is required for the 
process of gastrulation, where cells must acquire the ability to migrate in order to form 
new tissues and organs. However, this process may be also activated in differentiated 
cells, and in this case it may promote or accompany neoplastic transformation. Indeed, 
in carcinoma, the ability of epithelial transformed cells to migrate and reach metastatic 
sites depends on the dissolution of intercellular contacts and on the acquisition of 
motility (Thiery et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. EMT in cancer progression. Differentiated cells that undergo EMT, acquire a fibroblastike-
like morphology and acquire cancer features, such as drug resistance, ability to migrate and to form 
metastasis (from Wang et al., 2011). 
 
The induction of EMT in cancer can be influenced by extracellular context, and 
often by the interaction between epithelial cells and tumor environment, such as 
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fibroblasts, cytokines or other factors (TGFβ and EGF), that are normally present in the 
tumor microenvironment (Thiery and Sleeman, 2006); 
Molecular events (including mutations in oncogenes or oncosuppressor) 
affecting different steps in key biological processes are required to induce EMT and the 
acquisition of invasivity and motility. Moreover, EMT can be a transient event that is 
reverted (Mesenchymal to epithelial transition, MET). In particular, MET is important 
during the extravasation of metastatic cells from blood stream, in order to colonize the 
host organs and to form metastasis. All these observations indicate that EMT is a 
dynamic process, finely regulated in a cell specific context (De Craine and Berx, 2013). 
In several tumors, EMT has been related to specific features of cancer cells, for 
instance resistance to chemotherapy, resistance to anoikia, alteration in DNA repair 
invasion and ability to forms metastasis. Furthermore, EMT has been associated to the 
acquisition of stem cell-like phenotypes, suggesting a correlation between cell 
remodelling and re-programming of cellular functions (Visvader et al., 2012). 
During the last years, several studies stressed the importance of EMT in the 
acquisition of metastatic potential by PDAC cells. For instance, a study using murine 
models suggested that EMT occurs in the first stages of PanIN, promoting stemness and 
motility of cancer cells soon after the formation of the primary tumor (Rhim et al., 
2012). Moreover, there are evidences of the implication of EMT in another important 
feature of PDAC: the acquisition of resistance to chemotherapy, which is responsible 
for the failure of the treatment in advanced cancers (Wang et al., 2011, Arumugam et 
al., 2009) 
 
5.1 Regulation of EMT in cancer 
At the molecular level, EMT requires widespread reprogramming of gene 
expression that occurs through regulation of transcription, alternative splicing, 
expression of non-coding RNAs and translation (Figure 5.2).  
Regulation of transcription is one of the events that drive strong reprogramming 
in cells undergoing EMT (Puisieux et al., 2014). The first transcription factors identified 
for the induction of EMT were those involved in the down regulation of E-cadherin, one 
of the most important gene expressed in epithelial cells. The most relevant transcription 
factors identified for their action on E-cadherin transcription were SNAI1, known also 
as SNAIL (Batlle et al., 2000; Cano et al. 2000), SLUG (Hajra et al., 2006), ZEB1 
(Eger et al., 2002) and ZEB2 (Comijn et al., 2001). Over-expression of EMT-related 
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transcription factors also leads to repression of other genes encoding for proteins 
required for cell-to-cell contact, such as occludins and claudins (De Craene et al., 2005; 
Vandewalle et al., 2005). As a consequence, these transcription factors trigger a general 
reprogramming of cell shape and promote the expression of mesenchymal genes, such 
as vimentin, fibronectin and N-cadherin. Other transcription factors have been included 
among the inductors of EMT. The most relevant is TWIST, which is essential for 
metastatic potential in cancer cells (Yang et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Scheme of the principal rnetworks of the regulation of gene expression involved in the 
activation of EMT program (De Craene and Berx, 2013). 
 
EMT-related transcription factors involved in the repression of epithelial genes 
act through epigenetic mechanisms. Indeed, several histon-deacetylases (HDACs) and 
DNA methyl-transferases were associate with EMT transcription factors. For instance, 
SNAI1 exerts repression of the E-cadherin promoter through the recruitment of HDACs 
(Peinado et al., 2004) or histone methyl transferases (Herranz et al., 2008; Dong et al., 
2013). In the same way, ZEB1 repress E-cadherin expression through epigenetic 
modifications (Byles et al., 2012; Sanchez-Tillo et al., 2010), whereas TWIST is able to 
suppress E-cadherin expression by cooperating with an important chromatin 
remodelling factor: Bmi1 (Yang et al., 2010). The expression of all these factors and 
histone-remodelling proteins were found deregulated in many types of cancers (De 
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Craene and Berx, 2013), suggesting their important role in cell reprogramming and 
tumorigenesis. 
EMT is regulated also at the post-transcriptional level. On important step of 
regulation is the alternative splicing. Several differential splicing events are determinant 
for the epithelial or mesenchymal phenotype. For instance, two splicing factors, ESRP1 
and ESRP2, were found specifically expressed in epithelial cells, and they are important 
for the acquisition of epithelial features, by regulating the splicing of genes like MENA, 
CD44, CTNND1 and FGFR2 (Horiguchi et al., 2012). Therefore, overexpression of 
ESRP1/2 is able to induce radical changes of the splicing pattern in mesenchymal cells, 
reverting their phenotype, whereas down-regulation of ESRP1/2 in epithelial cells leads 
to up-regulation of mesenchymal genes (Warzeca et al., 2010). Moreover, the 
expression of ESRP1/2 is regulated by EMT related transcription factors, like ZEB1 and 
SNAIL (Horiguchi et al., 2012; Reinke et al.,2012).  
Another example of alternative splicing event involved in EMT is the exclusion 
of exon 11 of tyrosine kinase receptor RON, regulated by the first splicing factor known 
to have pro-oncogenic functions, SRSF1 (Ghigna et al., 2005; Karni et al., 2007). 
Skipping of exon 11 confers constitutive activity and pro- invasive properties to RON, 
determining EMT. All these observations indicate that alternative splicing represents an 
important post-trancriptional event that influences cancer progression and EMT. 
Another layer of regulation of gene expression that impacts on EMT is 
represented by miRNAs, which are crucial for the balance of different networks of 
EMT. For instance, the miRNA-200 family is required for the determination of the 
epithelial phenotype, and it is also a negative regulator of ZEB1 and ZEB2 expression 
(Park et al., 2008). Moreover, ZEB1 is able to inhibit the transcription of members of 
the miRNA-200 family, thus creating a negative loop, whose balance may be critical for 
the choice of epithelial or mesenchymal fate (Wellner et al., 2009; Brabletz and 
Brabletz, 2010). Like the miRNA-200 family, other miRNAs , such as miR-205 and 
miR-34, were linked to determination of the epithelial phenotype. MiR-205 and mi-
R34, in turn, can be transcriptionally regulated by EMT related transcription factors 
(Gregory et al., 2008; Siemens et al., 2011; Burk et al., 2008), and they were found 
down regulated in several kind of cancer, as breast, prostate and pancreatic carcinomas 
(Wellner et al., 2009; Kong et al., 2010; Tellez et al., 2011; Hur et al., 2013). 
Post-transcriptional regulation events, such as the regulation of mRNA 
translation, also play a key role in EMT. For instance, over-expression of the RNA 
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binding protein YB1 promotes cap-independent translation of SNAI1 and other EMT 
transcription factors (Evdokimova et al., 2009). Moreover, the stability of EMT-related 
transcription factors is regulated by post-translational modifications that regulate the 
protein turnover, and these processes are often aberrant in cancer cells (De Craene and 
Berx, 2013). 
In conclusion, transition of epithelial cells to a mesenchymal morphology is the 
result of cooperation of several pathways, which interact with each other in order to 
alter cell fate determination, underlines the complexity of the network that regulates this 
biological process.  
 
5.2 Role of ZEB1 in PDAC and genotoxic stress response 
 
5.2.1 ZEB1: structure and function 
Among the factors involved in EMT, ZEB1 is the most studied in PDAC, and 
several observations suggest the strong impact that ZEB1 exerts on resistance to 
chemotherapy, invasiveness and stemness-like properties of PDAC cells (Arumungam 
et al., 2009; Rhim et al., 2012). 
ZEB1 is a transcription factor that belongs to a small family of zing finger 
proteins, the ZEB family, composed by ZEB1 and ZEB2. It is characterised by the 
presence of two clusters of C2H2-type zinc finger domain separated by a homodomain 
(Figure 5.3). The zinc finger domains are required for the recognition and the binding of 
promoters of genes containing Z-boxes and E-boxes motif sequences (Remacle et al., 
1999). 
 
 
 
 
 
 
Figure 5.3. Schematic representation of ZEB1 structure and domain:  Co-activator  binding domain 
(CBP); Zing finger domain (ZNF); Smad binding domain (SBD); Homeodomain (HD); CtBP interaction 
domain (CID) (From Wellner et al., 2010). 
 
ZEB1 activity is regulated by the interaction with several factors, which 
modulate its ability to repress or activate gene transcription. For instance, ZEB1 induces 
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the activation of transcription of the ATPase1 gene in MDCK cells but it represses it in 
rat fibroblasts, suggesting a bivalent behaviour of ZEB1, which may depends on cellular 
context (Watanabe et al., 1993). The activity of ZEB1 can be activated by the TGFβ 
pathway, which causes activation of R-SMADs and their binding to the SMAD-binding 
domain (SMD) of ZEB1. Thus, the ZEB1-R-SMADs complex promotes repression of 
the E-cadherin promoter (Shirakihara et al., 2007). It has been proposed that the 
repressive activity of the ZEB1-SMAD complex depends on other ZEB1 co-interactors, 
such as p300/pCAF (Postigo et al., 2009). 
Activity of ZEB1 is regulated also at the post-translational level. For instance, 
SUMOylation is a frequent modification that occur in ZEB1, thus modulating its 
activity (Long et al., 2005). Furthermore, the interaction of CtBP1 and CtBP2 with the 
CID domain of ZEB1 favours its repressive activity on target genes, for instance E-
cadherin, through the recruitment of histone deacetylase, HDAC1 and HDAC2 
(Furusawa et al., 1999; Shi et al., 2003). 
These observations underline the fine regulation of ZEB1 activity, which is 
mediated by interaction with other binding factors, post-translational modifications and 
cellular context.  
 
5.2.2 ZEB1 in PDAC and genotoxic stress response 
Expression of ZEB1 is related with poor prognosis in several tumors, especially 
in PDAC.  Indeed, ZEB1 is expressed in PDAC tumor tissues and, importantly, its 
expression correlates with EMT and acquisition of resistance to gemcitabine treatment 
and other kind of genotoxic stresses in PDAC cell lines (Arumugan et al., 2009). 
Moreover, silencing of ZEB1 in PDAC cell lines that over-expresses it restore 
sensitivity to chemotherapeutic treatment (Arumungam et al., 2009; Wellner et al., 
2009). 
Since there is a correlation between ZEB1 expression and chemoresistance, 
ZEB1 expression could favour the selection of resistant cells population during stress 
condition, such as prolonged gemcitabine treatment. Indeed, it has been demonstrated 
that PDAC cells with acquired gemcitabine resistance over-expressed ZEB1 and show 
an induction of the EMT program mediated by the Notch-2 pathway (Wang et al., 
2009). 
Expression of ZEB1 correlates with EMT and its expression is regulated by the 
miRNA 200 family in PDAC (Wellner et al., 2009). The regulatory loop between 
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ZEB1/ZEB2 and miR200 was confirmed also in vivo (Kent et al., 2009). Moreover, the 
direct correlation between expression of miRNAs 200 and E-cadherin was found also in 
samples of patients with PDAC, where patients with a better prognosis have high 
expression of miRNAs belonging to miRNA-200 family (Yu et al., 2010).  
Expression of ZEB1 is also required for acquisition of cell motility and the 
ability to reach distal organs, and its correlates with acquisition of stemness in cancer 
cells in vitro and  in vivo (Rihm et al., 2012; Wellner et al., 2009). Furthermore, 
silencing of ZEB1 in PDAC cell lines reduces their tumorigenic potential, determining a 
decrease of tumor size derived from PDAC cells injected in a xenograft mouse model 
(Wellner et al., 2009). 
These data support the concept that ZEB1 and EMT are important for tumor 
transformation and progression in PDAC, promoting the acquisition of cellular features, 
such as chemoresistance and invasiveness, which are responsible for the poor prognosis 
in patients. 
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CHAPTER VI 
 
Genotoxic stress and DNA Damage Response (DDR) in PDAC 
 
Continuous replication in cancer cells is one of the most common features in 
tumors. Chemotherapy takes advantage of this hallmark, which is important to target 
cancer cells and to have less impact on normal cells, which normally do not proliferate 
in adult tissues. 
The chemotherapeutic agents that target replication of cancer cells are classified 
in: 
• alkylating agents, which bind covalently DNA and cause DNA damage during 
the replication; 
•  topoisomerase inhibitors, which inhibit the activity of the enzymes 
topoisomerase I and II during the initiation of replication of DNA, thereby 
imposing a physical stress and causing single strand- and double strand-breaks 
(SSB and DSB);  
• antimetabolite agents that are analogues of purynes and pyrimidines, which 
impair DNA and RNA synthesis. 
 
Chemotherapic drug used for PDAC treatment is gemcitabine, which is a 
cytidine analogue that is incorporated during S-phase into replicating DNA. When 
gemcitabine penetrates into the cells, it is phosphorylated by deoxycytidine kinase 
(DCK). Then, gemcitabine is converted by cytidine monophosphate kinase into cytidine 
diphosphate (dFdCDP) and then in triphosphate (dFdCTP) (Mini et al., 2006; Nakano et 
al., 2007). Both compounds inhibit the DNA synthesis, exerting an antiproliferative 
effect (Plunkett et al., 1995; Galmarini et al., 2002). 
 
6.1 The DDR pathway  
The incorporation of gemcitabine induces steric hindrance during the replication 
of DNA, causing the replication fork stalling, single strand breaks and the subsequent 
collapse of the replication fork (Huang et al., 1991). To prevent the collapse of the forks 
and induction of apoptosis, cells activate a program of stabilization of the fork in order 
to repair the damage and to recover DNA integrity (Lopes et al., 2001). Thus, 
gemcitabine triggers genotoxic stress in cancer cells, inducing the activation of 
pathways involved in the repair of DNA Damage. 
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The DNA damage response (DDR) pathways that are involved in the response to 
chemotherapeutic treatments rely on the Ataxia-Telangectasia Mutated (ATM) - 
Checkpoint Kinase 2 (CHK2) and the Ataxia-Telangectasia and Rad3 related (ATR) - 
Checkpoint Kinase 1 (CHK1) axes (Figure 6.1). Their action depends on the different 
DNA aberrant structures that form during DNA damage: ATM-CHK2 responds to DNA 
double strand breaks (DSBs) (Lee and Paull, 2007), whereas ATR-CHK1 responds to 
single strand breaks (SSBs) and stalled replication forks (Zou and Elledge, 2003). 
Moreover, factors that are recruited on the damage sites following ATM and ATR 
activation are different. Indeed, ATM recruits on DSBs the NMR complex, composed 
by NSB1, MRE11 and Rad50 (Lee and Paull, 2005), while ATR is recruited on DNA 
by Replication protein A, which binds ssDNA, and in turn interacts with HUS1-RAD9-
RAD1 complex (Delacroix et al., 2007). In both cases, ATM and ATR kinases have the 
role to signal the sites of the damage by mediating phosphorylation of Histone H2AX 
on Serine 139, also known as γH2AX (Fernandez-Capetillo et al., 2004, Ward and 
Chen, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Schematic representation of ATM and ATR pathway in DNA damage  response (from Smith 
et al., 2010). 
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The main effectors of ATM and ATR are, respectively, the kinases CHK2 and 
CHK1, albeit both ATM and ATR also phosphorylates other substrates that are 
important for the regulation of the DDR, such as, p53BP, MDM2 and BRAC1 (Smith et 
al., 2010). 
CHK2 is activated through the phosphorylation mediated by ATM. Once 
activated, CHK2 is dispersed into the nucleus and regulates several cellular of DDR, 
such as apoptosis, cell cycle progression and gene expression. For instance, CHK2 
regulates, togheter with CHK1, progression of cell cycle by phosphorylating members 
of the Cdc25 phosphatase family (Blasina et al., 1999). CHK2 influences cell cycle 
progression also by inhibiting p53 activity and by phosphorylating MDMX, a p53 
regulator (Chehab et al., 2000; Chen et al., 2005). Furthermore, CHK2 controls the 
activation the repair of DNA damage activating BRCA1 (Lee et al., 2000), acting in 
cooperation with BRCA2. 
CHK1, once activated by ATR, also controls cell cycle progression in response 
to DNA damage. Indeed, it phosphorylates and inactivates Cdc25 phosphatases, thus 
blocking cell cycle progression (Falck et al., 2002; Blasina et al., 1999). Inactivation of 
Cdc25 family phosphatases is required to repress the activity of Cdk2, thus blocking the 
formation of novel replication forks and preventing the collapse of the forks. Therefore, 
CHK1 is considered the main regulator of G1/S checkpoint during the inhibition of 
DNA synthesis, when cells must prevent the formation of novel replication origins 
(Branzei and Foiani, 2009). Moreover, upon activation of the DDR, CHK1 
phosphorylates BRCA2 and RAD51, and blocks transcription through the 
phosphorylation of histone H3 (Sorensen et al., 2005; Bahassi et al., 2008; Shimada et 
al., 2008).  
However, the ATM-CHK2 and ATR-CHK1 pathways are not completely 
independent and extensive crosstalk has been demonstrated between the two signalling 
cascades (Smith et al., 2010). For instance, when SSBs or replication forks are stalled, 
this defect leads to the induction of DSBs, allowing the activation of ATM and CHK2 
signalling, and both kisases cooperates to activates the repair or DNA Damage (Bahassi 
et al., 2008). Moreover, as mentioned before, CHK1 and CHK2 share the same 
substrates for the regulation of cell cycle progression as the members of Cdc25 family. 
Furthermore, more recently it has been proposed that ATM could enhance DDR 
stabilizing CHK1 protein (Zhang et al., 2014) Thus, ATM and ATR often co-participate 
to the DDR triggered by DNA damaging agents. 
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6.2 DDR in PDAC and during gemcitabine treatment 
Since the nucleoside analogs, like gemcitabine, mainly interfere with 
progression of the  replication forks during S-phase, the kinase that is immediately 
activated is CHK1 (Ewald et al., 2008). Accordingly, CHK1 has been demonstrated to 
be important for the recovery of DNA damage induced by gemcitabine treatment. 
Indeed, gemcitabine induces a strong activation of γH2AX, which was enhanced by 
depletion or pharmacological inhibition of CHK1, thus increasing the percentage of cell 
death (Edwald et al., 2007). It has been proposed that inhibition of CHK1 could be used 
in concomitance with inhibition of EGFR. Indeed, EGFR is up-regulated in up to 90% 
of PDAC (Tobita et al., 2003), and  inhibition of CHK1 activity in combination with 
gemcitabine and EGFR inhibitor decreases tumor burden in xenograft model mice 
injected with PDAC cells (Al-Ejeh et al., 2014). In this regard, it has been proposed that 
inhibition of CHK1 sensitizes PDAC cells to gemcitabine treatment by interfering with 
formation of RAD51 foci, which are required for the recovery of stalled forks, but 
without blocking the progression through S-phase (Parsels et al., 2009). 
Prolonged exposure of cells to gemcitabine also induces formation of DSBs and 
activation of the ATM pathway. Prolonged stalling of the replication forks leads to the 
persistence of BRAC1 and RAD51 foci, which in turn may induce cell death (Jones et 
al., 2014). Furthermore, it has been observed that prolonged treatment on PDAC cells 
with gemcitabine  induces phosphorylation of CHK2, which is required for cell survival 
and to prevent ROS-mediated stress (Duong et al., 2013). 
All these observations suggest the importance to counteract the ability of cells to 
repair DNA damage induced by chemotherapeutic treatment, which, concomitantly with 
the loss of cell cycle checkpoints, prevents the induction of apoptosis and cell death 
after DNA damage. 
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CHAPTER VII 
 
ZEB1 contributes to gemcitabine resistance and DNA damage response 
in PDAC cell lines. 
 
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive cancers in the 
western world, characterised by limited response to conventional chemotherapeutic 
treatments. At molecular level, mounting evidence suggests that resistance to 
chemotherapy in PDAC relies on a population of cells that undergoes a transition from 
an epithelial to mesenchymal phenotype. However, the mechanisms that confer 
resistance to gemcitabine, the standard chemotherapeutic approach for PDAC treatment, 
are not clearly understood. 
We found that the ability of PDAC cells to resist to gemcitabine treatment is 
correlated to their mesenchymal phenotype. Moreover, among the transcription factors 
involved in the acquisition of the mesenchymal phenotype, only ZEB1 clearly 
segregates resistant cells from sensitive cells. Silencing of ZEB1 in resistant cell lines 
impairs cell viability, even in absence of chemotherapeutic treatments. Furthermore, 
silencing of ZEB1 induces a higher number of dead cells in the ZEB1-silenced 
population. Our results suggest the involvement of ZEB1 in the ability to respond to 
DNA damage caused by gemcitabine treatment. In particular silencing of ZEB1 impairs 
the activation of phosphorylation of CHK2, and it might play a role also in the 
maintenance of genome stability in cells that express higher level of this transcription 
factors.  
Thus, our data strongly indicate a novel role for ZEB1 in the mechanisms of 
resistance to gemcitabine treatments in PDAC cells, which may be suitable to overcome 
resistance to chemotherapy in PDAC.  
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INTRODUCTION  
Pancreatic ductal adenocarcinoma (PDAC) is a common cause of death among 
solid cancers in the western world. Despite improvements in surgical techniques and 
new chemotherapeutic agents, outcome for patients remains extremely poor, displaying 
a median survival of less than one year from diagnosis and overall 5-year survival lower 
than 5% (Kern et al., 2011). Gemcitabine, the current standard first-line treatment, 
offers only marginal benefits to patients in terms of symptom control and prolongation 
of life.  
To date, no clear molecular characterization of the drug resistant phenotype of 
pancreatic cancer cells is available. At molecular level, recent evidence suggests that 
resistance to chemotherapeutic treatment in PDAC cells is associated with an increased 
migratory and invasive phenotype. This process, also known as Epithelial-to-
mesenchymal transition (EMT), occurs in differentiated epithelial cells during tumor 
transformation, allowing tumor cells to increase their ability to migrate and invade distal 
tissues (De Craine and Berx, 2013). A number of observations indicate that EMT 
contributes to the malignant phenotype and drug resistance in PDAC cells, suggesting 
that this event plays a key role in the acquisition of chemoresistance (Arumugam et al., 
2009; Wellner et al., 2009). EMT is characterised by profound changes in gene 
expression, which involve transcriptional and post-transcriptional events. In particular, 
at the transcriptional level, EMT is orchestrated by several transcription factors, that 
repress the expression of epithelial genes. Among all the transcription factors involved 
in the induction of EMT in PDAC, expression of ZEB1 plays an important role in the 
acquisition of chemoresistance to several agents (Arumugam et al., 2009, Wellner et al., 
2009). Moreover, expression of ZEB1 in early EMT events in PanIN (Pancreatic 
Intraepithelial neoplasia) determines dissemination of metastatic cells, which precedes 
the formation of primary tumors (Rhim et al., 2012). To date, although expression of 
ZEB1 and induction of EMT have been correlated with chemoresistance of cancer cells, 
how ZEB1 induces this phenotype is still largely unknown.  Recently, a role for ZEB1 
in the DNA damage response (DDR) has been proposed. ZEB1 was shown to interact 
with and stabilize CHK1, a protein kinase involved in DNA repair by homologous 
recombination, thereby enhancing the resistance to radiotherapy of breast cancer cells 
(Zhang et al., 2014). Indeed, enhancement of the DDR pathway is one of the features of 
cancer cells, which determines acquisition of drug-resistance. 
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In the present work, we investigated the mechanisms by which ZEB1 determines 
gemcitabine resistance in PDAC cell lines. We found that PDAC cells that are able to 
respond to gemcitabine treatment show a mesenchymal phenotype, whereas sensitive 
cell lines express epithelial markers. Moreover, we found that silencing of ZEB1 affects 
basal cell viability and increases number of dead cells in the ZEB1-silenced population. 
The restoration of sensitivity to gemcitabine, however, is not related to reversion of the 
mesenchymal phenotype to an epithelial one, suggesting that maintenance of a 
mesenchymal phenotype is not sufficient for gemcitabine resistance. However, we found 
that silencing of ZEB1 affects phosphorylation of Checkpoint Kinase 2 (CHK2) during 
gemcitabine treatment, suggesting that ZEB1 may be important for response to 
genotoxic stress by sustaining a robust DDR. Thus, our results suggest a novel scenario, 
in which ZEB1 is required to enhance response to genotoxic stress and progression of 
cell cycle in aggressive PDAC cells, highlighting novel mechanisms that are required 
for gemcitabine resistance. 
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RESULTS 
 
PDAC cell lines show different sensitivity to gemcitabine treatment 
In order to investigate the molecular mechanisms that underline gemcitabine 
resistance in PDAC, we tested cell viability in a panel of PDAC cell lines in presence of 
increasing doses of gemcitabine. We selected a non tumoral cell line derived from 
immortalized pancreatic ductal cells, the HPDE cell line, as control, and other cell lines 
derived from primary PDAC tumors, the HPAF-II, MiaPaCa-2 and Pt45P1 cell lines. 
Their sensitivity to gemcitabine treatment was tested by performing clonogenic assays 
(Figure 1A). We found that the control line HPDE is the most sensitive to gemcitabine, 
while tumoral cell lines are more resistant. However, tumor cell lines display different 
sensitivity to the drug. HPAF-II cells show the highest sensitivity, while Pt45P1 and 
MiaPaCa-2 cells are more resistant. However, MiaPaCa-2 results the most resistant cell 
line, showing a higher percentage of colony numbers with respect to Pt45P1. To confirm 
these results by a different approach, we performed western blot analysis of the cleaved 
form of the pro-apoptotic protein PARP (Figure 1B). In line with the clonogenic assay, 
HPDE and HPAF-II cells show an increased ratio of cleaved PARP/full length PARP at 
higher doses of gemcitabine (10 uM-1 mM) than Pt45P1 and MiaPaCa-2 cells. 
It is known that PDAC cells with higher sensitivity to multidrug treatments have 
an epithelial phenotype (Arumungam et al., 2009). To investigate if sensitivity of cells 
analyzed is related to the expression of epithelial or mesenchymal markers, we analyzed 
the expression of E-cadherin (for the epithelial phenotype) and vimentin (for the 
mesenchymal phenotype) through RT-PCR (Figure 1C) and western blot (Figure 1D). 
Our results show cell lines sensitive to gemcitabine treatment (HPDE and HPAF-II) 
express E-cadherin, whereas resistant cell lines (MiaPaCa-II and Pt45P1) express 
Vimentin.  
Altogether, our results indicate that the mesenchymal phenotype of PDAC cells 
is associated with increased resistance to gemcitabine. 
 
ZEB1 is expressed in resistant PDAC cell lines 
During PDAC development, cancer cells may undergo EMT, which confers to 
cancer cells the ability to detach from the primary tumor and invade other organs (Rhim 
et al., 2012). At the molecular level, several transcription factors are crucial for the 
induction of the transition. In order to investigate if the resistance of mesenchymal 
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PDAC cell lines depends on the expression of specific transcription factors, we analyzed 
the mRNA expression of a subset of transcription factors involved in the EMT (SNAIL, 
SLUG and ZEB1). Analysis of mRNA expression shows that, among all the 
transcription factors analyzed, only ZEB1 clearly segregates resistant and mesenchymal 
cells from sensitive and epithelial cells (Figure 2A). These results were also confirmed 
by the western blot analysis (Figure 2B).  
Thus, our results suggest that ZEB1 expression is correlated to mesenchymal 
phenotype and gemcitabine resistance in PDAC cell lines. 
 
ZEB1 affects cell viability in PDAC cell lines 
Expression of ZEB1 has been related to resistance to multidrug treatment, 
including gemcitabine, in PDAC cell lines (Arumugam et al., 2009). Moreover, it has 
also been shown that ZEB1 plays a role in the acquisition of pro-metastatic behaviour of 
PDAC cells, and that genes involved in EMT can be involved in “oncogene addiction” 
and cell viability in mesenchymal cells (Singh et al., 2009) 
In order to investigate if ZEB1 is involved in PDAC cells viability, we silenced 
it transiently in cell lines expressing high levels of ZEB1 (MiaPaCa-2 and Pt45P1). 
Notably, we found that ZEB1 knockdown impairs cell proliferation and cell viability 
under basal conditions (Figure 3A-B), indicating that ZEB1 is involved in the control of 
these processes in PDAC cells. Furthermore, treatment with gemcitabine showed higher 
number of dead cells in the ZEB1-silenced population with respect to cells silenced with 
a control siRNA (Figure 3B). However, this effect was not accompanied by increased 
sensitivity to the drug, but it likely reflected the increased basal levels of death observed 
in the cells silenced for ZEB1.  
EMT has been previously proposed as a mechanism to acquire drug resistance in 
PDAC cells. However, transient silencing of ZEB1 in PDAC cells did not affect 
expression of vimentin nor it increased the expression of E-cadherin (Figure 4A-B). 
Moreover, ZEB1 knockdown did not induce significant changes in cellular shape and 
morphology (Figure 4C-D), suggesting that the increase in cell death and the inhibition 
of cell proliferation is not correlated to transition from mesenchymal to epithelial-
phenotype in the PDAC cells analyzed. 
Thus, our results suggest that silencing of ZEB1 impairs proliferation in PDAC 
cells and increases the number of dead cells, both under both basal conditions and in 
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response to gemcitabine treatment, without triggering a mesenchymal-to-epithelial 
transition (MET). 
 
Different activation of the DDR response in epithelial and mesenchymal PDACs 
cell lines  
In order to understand the mechanisms by which ZEB1 regulates response to 
gemcitabine treatment, we analyzed the DDR pathway. Recently, it was found that 
ZEB1 is involved in the response to radiation therapy in breast cancer (Zhang et al., 
2014). In particular, expression of ZEB1 stabilizes the Checkpoint Kinase 1 (CHK1) 
protein and enhances the ability of cells to repair DNA damage induced by radiation. 
We analyzed the induction of the DDR by gemcitabine treatment in two cell 
lines that are sensitive and resistant to drug treatment. We selected HPAF-II and 
MiaPaCa-II cell lines, and we tested increasing doses of gemcitabine (0,1 µM - 1 mM). 
Both HPAF-II and MiaPaCa-2 readily activated phosphorylation of Histone H2AX in 
Serine 139 (γH2AX), starting from the dose of 10 µM of the drug (Figure 5A). 
Concomitantly, gemcitabine induces the activation of Ataxia-telancgectasica mutated 
(ATM), through the activation of its phosphorylation on Ser 1981 (Figure 5A). These 
data suggest that both cell lines readily induce the DDR at the dose of 10 µM. 
In order to understand if the expression of ZEB1 affects the activation of CHK1 
and CHK2, the downstream effectors of DDR response, we performed a time course of 
gemcitabine treatment at the dose of 10 µM. In both HPAF-II, which does not express 
ZEB1, and MiaPaCa-2, that express ZEB1, gemcitabine induces an early activation of 
the phosphorylation of CHK1 (Figure 5B). However, CHK1 activation persists in 
MiaPaCa-2 until 72 hours, while it is inhibited at 48 hours in HPAF-II. Moreover 
gemcitabine induces a sustained activation of CHK2 phosphorylation in MiaPaCa-2, 
whereas its activation was not detected in HPAF-II. 
These data suggest a different activation of the downstream effectors of the 
DDR in HPAF-II and MiaPaCa-2 cells, which may underline their different sensitivity 
to gemcitabine treatment. 
 
ZEB1 regulates the activation of p-ATM and CHK2 in PDAC cell lines 
In order to understand if ZEB1 is involved in the stronger activation of CHK1 
and CHK2 in MiaPaCa2 cells, we silenced it and evaluated the DDR pathway during 
treatment with gemcitabine (Figure 6). Notably, we found that silencing of ZEB1 does 
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not impair the activation of CHK1. On the contrary, silencing of ZEB1 almost 
completely abolished activation of CHK2 and induction of ATM phosphorylation 
(Figure 6). 
These results suggest that ZEB1 regulates the activation of CHK2 during 
gemcitabine treatment, providing a possible mechanism for the involvement of ZEB1 in 
the response to gemcitabine treatment. 
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DISCUSSION 
Understanding the mechanisms involved in the acquisition of chemoresistance in 
PDAC is one of the most important steps to improve the prognosis for this disease, 
which remains still incurable for advanced stages. 
In our work we have investigated the mechanism(s) that PDAC cells set in 
motion in order to resist to gemcitabine treatment. We tested the ability three PDACs 
cell lines, HPAF-II, Pt45P1 and MiaPACa-2, to respond to gemcitabine, in comparison 
to a non-tumor cell line, HPDE. We found that MiaPaCa-2 and Pt45P1 were more 
resistant than HPAF-II to treatments, and higher resistance was correlated with their 
mesenchymal phenotype. Moreover, among the transcription factors known to be 
involved in the determination of the mesenchymal phenotype, only ZEB1 expression 
specifically correlated with the mesenchymal phenotype and gemcitabine resistance of 
PDAC cell lines. Silencing of ZEB1 impaired cell proliferation and enhanced basal cell 
death, affecting in turn also viability in response to gemcitabine.  
It is known that ZEB1 plays a role in the acquisition of multidrug 
chemoresistance in PDAC cell lines (Arumungam et al., 2009), and that silencing of 
ZEB1 is important to reduce the metastatic potential also in vivo in PDAC (Wellner et 
al., 2009). Furthermore, expression of ZEB1 in pancreatic cells may occur in the third 
stage of Pancreatic intra-neoplasia (PanIN-3), before the formation of primary tumor 
and promoting the detachment of metastatic cells (Rhim et al., 2012). ZEB1 plays a key 
role in drug resistance and in tumoral potential also in other cancers, such as breast 
cancer, melanoma and glioblastoma (Chaffer et al., 2013, Caramel et al., 2013, 
Siebzehnrubl et al., 2013). Thus, these data suggests that ZEB1 potentially takes part of 
cell mechanisms which impact on tumor transformation. Nevertheless, the mechanisms 
by which ZEB1 regulates drug-resistance and malignancy of tumors cells are still 
unknown. 
Notably, we found that silencing of ZEB1 is able to impair basal cell viability in 
MiaPaCa-2 cell lines. It has been demonstrated that EMT factors may be important in 
the regulation of cell survival in PDAC and lung cell lines which display a KRAS-
independence for cell viability (Singh et al., 2009). Thus, our results suggest a possible 
addiction of mesenchymal PDAC cells to ZEB1 for cell survival, and highlight the key 
role of ZEB1 in cancer cells. 
Our results show that silencing of ZEB1 increase the percentage of cell death in 
presence of gemcitabine, even in the absence of reversal to an epithelial phenotype. 
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Therefore, our data suggest that mechanisms other than loss of a mesenchymal 
phenotype are involved in gemcitabine resistance of PDAC cells. Recently, it has been 
proposed a novel role for ZEB1 in the protection to DNA damage induced by 
radiotherapy (Zhang et al., 2014). ZEB1 was shown to enhance the ability of cancer 
cells to recover DNA damage after exposure to radiotherapy, through stabilization of 
CHK1. This effect was mediated by phosphorylation of ZEB1 by ATM. Hence, the 
crosstalk beetwen ZEB1 and ATM appears to be important for the acquisition of 
resistance to radiotherapy.  In order to understand if ZEB1 regulates the response to 
DNA damage induced by gemcitabine, we analyzed the activation of the DDR in 
MiaPaCa-2 and HPAF-II, which respectively express or not ZEB1. Gemcitabine 
induced the same activation o γH2AX and p-ATM in both cell lines, starting from the 
10 µM dose. However, the activation of the downstream effectors of the DDR, CHK1 
and CHK2, was different in HPAF-II and MiaPaCa-2. Indeed, phosphorylation of p-
CHK1 is maintained until 72 hours in MiaPaCa-2 cells, while in HPAF-II cells is 
inhibited at 48 hours. Moreover, phosphorylation of CHK2 is activated in MiaPaCa-2 
cells, whereas is not induced in HPAF-II cells. In order to understand if ZEB1 is 
involved in the activation of CHK1 or CHK2 we silenced ZEB1 in MiaPaCa-2 cells. 
Notably, the absence of ZEB1 affected the activation of CHK2 but not CHK1. 
Intriguingly, silencing of ZEB1 affected also the activation of p-ATM, suggesting that 
ZEB1 may affect CHK2 phosphorylation by impairing ATM activation. Previous data 
indicated that silencing of ATM in tumor cells affected response to gemcitabine 
treatment (Karnitz et al., 2005). Moreover, fibroblasts depleted of ATM are sensitized 
to gemcitabine and their repopulation capability was impaired after drug exposure 
(Ewald et al., 2008). These data suggests that ZEB1 could regulate the DDR by 
modulationg ATM activation. 
However, CHK2 activation downstream of ATM may also be fundamental for 
DDR in response to gemcitabine. Indeed, inhibition of CHK1 and CHK2 sensitizes 
PDAC and other cancer cells to gemcitabine treatment (Karnitz et al., 2005; Matthwes 
et al., 2007). In line with this observation, depletion of CHK2 or pharmacological 
inhibition of CHK2 in MiaPaCa2 cells sensitized them to gemcitabine treatment, 
promoting formation of ROS-agents which increased cell death. Thus, activation of the 
ATM/CHK2 pathway is required for PDAC cells to improve the response to 
gemcitabine treatment.  
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In conclusion, our work proposes a novel role for ZEB1 in the acquisition of 
gemcitabine resistance through the regulation of the ATM-CHK2 pathway. Thus 
counteracting this DDR pathway or ZEB1 expression in cells resistant to gemcitabine 
may enhance the effect of chemotherapy on treatment of advanced PDAC. 
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MATERIALS AND METHODS 
 
Cell Culture and treatments 
HPDE, HPAF-II and Pt45P1 were cultured in RPMI 1640 medium (Lonza), 
MiaPaCa-2 was cultured in DMEM medium (Lonza). Both media were supplemented 
with 10% fetal bovine serum (Gibco), penicillin and streptomycin. Cells were growth in 
a 37°C humidified atmosphere of 5% CO2. Gemcitabine (Eli Lilly & Company, 
Indianapolis, IN, USA) was dissolved in water and stored at -20 °C. 
  
Cell transfections 
For RNA interference, cells at ~50-60% confluence were transfected with 
siRNAs (Sigma- Aldrich) using Lipofectamine RNAiMAX (Invitrogen) and OptiMEM 
medium (Invitrogen), according to the manufacturer’s instructions. Briefly, PDAC cells 
were transfected with 50 nM of ZEB1 or control siRNA. At the end of transfection, 
cells were tripsinized and seeded for Trypan Blue Count, MTS assay, 
immunofluorescence and for protein extraction.  Sequences of ZEB1 and control siRNA 
are listed in Table 1. 
 
RT-PCR analysis 
Total RNA was extracted from cells using Trizol reagent (Invitrogen) according 
to the manufacturer’s instructions. After digestion with RNase free DNase (Ambion), 
RNA was resuspended in RNase free water (Sigma Aldrich); 1µg of total RNA was 
retrotranscribed using M-MLV reverse transcriptase (Promega). Five percent of the 
retrotranscription reaction was used as template for PCR analysis (GoTaq, Promega). 
Primers used are listed in Table1. 
 
Protein extraction and Western blot analysis 
For protein extraction, cells were resuspended in lysis buffer (100mM NaCl, 
15mM MgCl2, 30mM Tris-HCl pH 7.5, 1mM dithiothreitol, 2mM Na-ortovanadate, 
Protease-Inhibitor Cocktail (Sigma-Aldrich) and 1% Triton X-100). After 10 min of 
incubation in ice, the extracts were centrifuged for 10 min at 12,000 rpm at 4°C and the 
supernatants were resuspended in SDS-page sample buffer, and boiled for 5 minutes. 
Western blot analysis was performed as previously described (Di Florio et al., 2007). 
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Following primary antibodies (overnight at 4°C) were used: rabbit anti-Actin (1:1000, 
Sigma Aldrich), mouse anti-GAPDH (1:1000, Santa Cruz Biotechnology), rabbit anti-
E-cadherin (1:1000, Santa Cruz Biotechnology), mouse anti-Vimentin (1:1000, Santa 
Cruz Biotechnology), rabbit anti-ZEB1 (1:1000, Sigma-Aldrich), mouse anti-pATM 
Serine 1981 (1:1000, Cell Signalling Technology), rabbit anti p-CHK2 Threonine 68 
(1:1000, Cell Signalling Technology), rabbit anti p-CHK1 Serine 296 (1:1000, Cell 
Signalling Technology), rabbit anti p-H2AX Serine 139 (1:1000, Cell Signalling 
Technology). Secondary anti-mouse or anti-rabbit IgGs conjugated to horseradish 
peroxidase (Amersham) were incubated for 1 h at RT (1:10000). Immunostained bands 
were detected by chemiluminescence method (Santa Cruz Biotechnology). 
 
Coomassie staining 
After separation on 10% SDS-PAGE, protein bands were visualized by placing 
gels in a solution of 40% distilled water, 10% acetic acid, and 50% methanol with the 
addition of 0.25% by weight Coomassie Brilliant Blue R-250 (Sigma-Aldrich). Gels 
were incubated 2 hours at room temperature and then washed  in a mixture of 40% 
distilled water, 10% acetic acid, and 50% methanol by shaking for 1 hour. The washing 
mixture was replaced with fresh rinse mixture until the excess dye has been removed. 
 
Colony formation assay 
Single-cell suspensions were plated in 35mm plates (500 cells/plate for Pt45P1 
and MiaPaCa-2; 700 cells/plate for HPDE and HPAF-II). After 1 day, cells were treated 
for 24 h with gemcitabine. At the end of the incubation, the medium was replaced every 
48 h. After 10 days, cells were fixed in methanol for 10 min, stained overnight with 5% 
Giemsa (Sigma Aldrich), washed twice in PBS and dried. Pictures were taken using a 
digital camera to count and measure the colonies. Results represent the mean of at least 
3 experiments ±s.d. 
 
Trypan Blue and viability assay 
For Trypan Blue Assay, PDAC cells were seeded at ~70% confluence in 24-well 
plate and treated as described in the text for 72 h, washed in PBS and trypsinized. 
Cellular suspension was incubated with of 0.4% Trypan Blue Stain (Invitrogen) and 
cells were counted using Cell Countess II System (Invitrogen). Cell viability was 
measured by the MTS Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay 
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(Promega) according to manufacturer’s instructions by plating 2000 cells (MiaPaCa2) 
or 3000 cells (PT45P1) per well. Results of Trypan blue and cell viability assays 
represent mean±s.d. of three experiments. 
 
Immunofluorescence analysis 
For phalloidin analysis, PDAC cells were fixed in 4% paraformaldehyde and 
washed three times with PBS. Cells were permeabilized with 0.1% Triton X-100 for 10 
min and incubated for 1 h in 3% BSA. Cells were washed three times with PBS and 
incubated for 1 h at room temperature with antibodies (anti-phalloidin 1:400, Sigma-
Aldrich). Slides were a mounting solution with Hoechst dye (Invitrogen). At least 200 
cells for each experiment were acquired. 
 
 
Table 1: List of oligos used in this study 
 
Oligo name Sequence 5’3’ Reference 
E-Cadherin FW AGTTTTCCACCAAAGTCACGC This study 
E-Cadherin RV AGGAGTTGGGAAATGTGAGCA This study 
Vimentin FW AGACACTATTGGCCGCCTGCAGGATG This study 
Vimentin RV GAAGAGGCAGAGAAATCCTGCTCTCCTCGCCTTCCA This study 
ZEB1 FW CATTGCTGACCAGAACAGTGTTCC This study 
ZEB1 RV TGGGCGGTGTAGAATCAGAGTCAT This study 
SNAIL FW CACTATGCCGCGCTCTTTC Evdokimova, 2009 
SNAIL RV GCTGGAAGGTAAACTCTGGATTAGA Evdokimova, 2009 
SLUG FW AGTCCAAGCTTTCAGACCCCCATGCCATTG Valacca, 2010 
SLUG RV TTCTCCCCCGTGTGAGTTCTA Valacca, 2010 
HPRT FW TGACCAGTCAACAGGGGACA This study 
HPRT RV TTCGTGGGGTCCTTTTCACC This study 
Si CTRL AGACGAACAAGUCACCGAC This study 
Si ZEB1 AGAUGAUGAAUGCGAGUCG Wellner, 2009 
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FIGURE LEGENDS 
 
Figure 1. PDAC cell lines show different sensitivity to gemcitabine treatment. A) 
Western Blot analysis of the total protein PARP and the cleaved-isoform in PDAC cells 
treated with different doses of gemcitabine for 72 hours. Actin was used as loading 
control. B) Histograms represent the percentage of inhibition of colony formation in 
comparison to control cells from three experiments (mean ± s.d.). Statistical analysis 
was performed by the paired Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01. C) RT-PCR analysis 
in PDAC cell lines of E-cadherin and Vimentin genes. HPRT was used as loading 
control. D) Western Blot analysis of E-cadherin and Vimentin Protein in pDAC cell 
lines. Coomassie Staining was used as loading control. 
 
Figure 2. ZEB1 is expressed in resistant PDAC cell lines. A) RT-PCR analysis of 
EMT transcription factors genes ZEB1, SLUG and SNAIL. HPRT was used as loading 
control. B) Western blot analysis of ZEB1 in PDAC cell lines. Coomassie staining was 
used as loading control. 
 
Figure 3. ZEB1 affects cell viability in PDAC cell lines. A) Histograms represent 
MTS analysis of MiaPaCa-2 and Pt45P1 cells transfected with a control or ZEB1 
siRNA. B) Trypan Blue analysis of cells transfected as in (A) treated or not with the 
indicated doses of gemcitabine. Statistical analysis was performed by the paired 
Student’s t-test; * P ≤ 0.05, ** P ≤ 0.01. 
 
Figure 4. Transient silencing of ZEB1 does not revert mesenchymal phenotype. A-
B) Western Blot analysis of ZEB1, E-Cadherin and Vimentin protein level. GAPDH 
was used as loading control. C-D) Representative images of PDAC cells transfected 
with a control or ZEB1 siRNA in bright field (C) or stained with phalloidin (D) (40X 
magnifications). 
 
Figure 5. PDACs cell lines display a different activation of DDR response. A) 
Western Blot analysis in HPAF-II and MiaPaCa-2 for p-ATM and γH2AX in presence 
of gemcitabine, as indicated in figure. B) Western Blot analysis in HPAF-II and 
MiaPaCa-2 for p-ATM, p-CHK2, p-CHK1 and γH2AX in presence of gemcitabine 10 
µM at the times indicated in figure. Actin and GAPDH were used as loading control for 
the western blot analysis. 
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Figure 6. ZEB1 regulates the activation of p-ATM and CHK2 in PDAC cell lines. 
Western Blot analysis MiaPaCa-2 transfected with control or ZEB1 si RNAs for p-
ATM, p-CHK2, p-CHK1 and γH2AX in presence of gemcitabine 10 µM at the times 
indicated in figure. GAPDH was used as loading control for all the western blot 
analysis. 
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APPENDIX 
 
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine 
resistance in pancreatic cancer cells. 
 
Acquisition of resistance to gemcitabine treatment in PDAC represents one of the most 
important causes of the poor prognosis for this disease.  In the present work we have 
investigated the possible mechanisms which underline resistance to chemotherapy in PDAC. 
Our work highlights the role of alternative splicing and its deregulation in cancer progression 
and drug resistance. 
We established a subpopulation of cells that are resistant to drug treatment through the 
chronic exposure of PDAC cell lines to gemcitabine. We obtained a drug-resistant sub-
population (DR-PDAC cells) with higher ristance to gemcitabine and cisplatin with respect to 
the parental cell lines (PCL-PDAC cells). In order to investigate the mechanisms responsible 
for the gemcitabine resistance, we analyzed a subset of AS events known to be important in 
cancer progression. We found that the AS of the pyruvate kinase gene, PKM, is differentially 
regulated in DR-cells with respect to PCL cells. Indeed, the PKM2 splicing isoform is 
favoured in DR-cells, and PKM2 expression correlates with  poor prognosis in tumor samples 
of PDAC. Moreover, by reverting the splicing of PKM2 to the PKM1isoform using splicing-
specific antisense oligonucleotides (ASO), we restored the sensitivity of DR-cells to 
gemcitabine and cisplatin, suggesting a role of PKM2 in the acquisition of resistance to 
chemotherapeutic treatment. In order to understand the mechanisms responsible for the 
selection of PKM2 variant respect with PKM1, we analyzed the expression of splicing factors 
known to be involved in the regulation of PKM splicing. We found that expression of the 
polypiridine-tract binding protein 1 (PTBP1) correlates with the PKM2 splicing variant. 
Importantly, we found that PTB1 is recruited on PKM pre-mRNA with higher efficiency in 
DR-cells respect with PCL-cells, and silencing of PTBP1 in DR-cells causes a decrease of the 
recruitment of PTB1 on PKM pre-mRNA. Notably, silencing of PTBP1 causes the switching 
of PKM splicing in DR-cells, determining an increase of PKM1 isoform, concomitantly with 
a restoration of gemcitabine sensitivity. 
In conclusion, our study demonstrated that chronic treatment with gemcitabine in 
PDAC cell lines determines the selection of cells with a drug-resistant phenotype, which may 
be selected by the deregulation of PKM AS. Thus, our study demonstrated that the PKM2 
variant and the splicing factor PTBP1 may represent targetable molecular events to prevent 
the acquisition of the chemoresistant phenotype and to improve the prognosis in PDAC. 
This work has been accepted for publication in Oncogene on June 8th, 2015. 
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Abstract  
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is 
due to multiple reasons, including acquisition of resistance to gemcitabine, the first line 
chemotherapeutic approach. Thus, there is a strong need for novel therapies, targeting more directly 
the molecular aberrations of this disease. We found that chronic exposure of PDAC cells to 
gemcitabine selected a subpopulation of cells that are drug-resistant (DR-PDAC cells). Importantly, 
alternative splicing of the pyruvate kinase gene (PKM) was differentially modulated in DR-PDAC 
cells, resulting in promotion of the cancer-related PKM2 isoform, whose high expression also 
correlated with shorter recurrence free survival in PDAC patients. Switching PKM splicing by 
antisense oligonucleotides to favour the alternative PKM1 variant rescued sensitivity of DR-PDAC 
cells to gemcitabine and cisplatin, suggesting that PKM2 expression is required to withstand drug-
induced genotoxic stress. Mechanistically, up-regulation of the polypyrimidine-tract binding protein 
(PTBP1), a key modulator of PKM splicing, correlated with PKM2 expression in DR-PDAC cell 
lines. PTBP1 was recruited more efficiently to PKM pre-mRNA in DR- than in parental PDAC 
cells. Accordingly, knockdown of PTBP1 in DR-PDAC cells reduced its recruitment to the PKM 
pre-mRNA, promoted splicing of the PKM1 variant and abolished drug resistance. Thus, chronic 
exposure to gemcitabine leads to up-regulation of PTBP1 and modulation of PKM alternative 
splicing in PDAC cells, conferring resistance to the drug. These findings point to PKM2 and 
PTBP1 as new potential therapeutic targets to improve response of PDAC to chemotherapy. 
? ?
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers, being 
characterized by very low 5-year survival rate (1). Lack of early symptoms and late diagnosis 
contribute to poor prognosis, with most patients presenting with metastasis. When surgical resection 
is unfeasible, chemotherapy with gemcitabine, administered either alone or in combination with 
other compounds, represents the clinical option for PDAC. Nevertheless, relapse always occurs 
with more aggressive features and insensitivity to chemotherapy, contributing to high lethality (2,3). 
Thus, identification of new diagnostic markers and elucidation of the molecular pathways involved 
in acquisition of drug resistance represent clinical priorities for PDAC (2,4). 
 
Adaptation to variable stresses is a key feature of neoplastic cells. Recent evidence 
highlighted how cancer cells can flexibly modulate gene expression at the level of alternative 
splicing (AS) to withstand hostile conditions (5-8). In this regard, changes in expression of some 
splicing factors have been directly linked to expression of oncogenic splice variants that confer 
various advantages to cancer cells (9-14). Moreover, genotoxic stress was shown to modulate 
splicing regulation (15), in some cases by affecting the localization or activity of specific splicing 
factors, such as SAM68 (16) or EWS (17). In the case of PDAC cells, it was previously shown that 
increased expression of the serine/arginine (SR)-rich protein kinase SRPK1, a prototypic splicing 
factor kinase, confers resistance to treatment with gemcitabine (18). Notably, since SRPK1 
modulates the activity of several SR protein splicing factors with implication in cancer (19), 
including SRSF1 (20), it is likely that up-regulation of this kinase contributes to the expression of 
oncogenic splice variants expressed in PDAC cells (21). 
Herein, we aimed at investigating the role of AS and splicing factors in the acquisition of a 
drug-resistant (DR) phenotype in PDAC cells. We observed that chronic treatment with 
gemcitabine promoted the formation of DR subpopulations highly resistant to drug-induced 
genotoxic stress. In order to understand the contribution of AS to the DR phenotype, we analyzed a 
? ?
group of cancer-related splice variants involved in oncogenic features (5-8). We found that DR- 
PDAC cells exhibited a switch in PKM AS, a gene encoding two alternative splice variants, PKM1 
and PKM2, through usage of mutually exclusive exons. PKM2 is typically expressed in cancer cells 
where it confers oncogenic features (22- 24). We show that splicing of PKM2 is favoured in DR-
PDAC cells with respect to the parental cells and promotes drug resistance, as interference with this 
splicing event in DR-PDAC cells restored sensitivity to gemcitabine and cisplatin. Mechanistically, 
we demonstrate that the polypyrimidine-tract binding protein PTBP1 is up-regulated in DR-PDAC 
cells and that its increased recruitment to the PKM pre-mRNA promotes PKM2 splicing. 
Knockdown of PTBP1 in DR-PDAC cells reduces its binding to PKM pre-mRNA, favours the 
expression of PKM1 and rescues drug sensitivity. Hence, our results indicate a positive role for 
PTBP1 and PKM2 in the acquisition of drug resistance, suggesting that this regulatory pathway 
represents a novel potential therapeutic target for PDAC.? ? ?
? ?
Results 
Isolation of drug-resistant (DR)-PDAC cells 
To isolate drug-resistant (DR) PDAC cell sub-populations, we exposed to chronic treatment 
with gemcitabine (10 ?M) two cell lines: Pt45P1, which displays higher sensitivity to the drug, and 
PANC-1, which is more resistant to treatment (Supplementary Figure 1A). As expected, 
gemcitabine caused massive cell death in both cell lines in the seven days of treatment. However, 
15 days after removal of the drug, few viable clones were visible in the plates of both cell lines. 
Clones were pooled, amplified and cultured by exposing them to a 24 hour-pulse of gemcitabine 
every other week to maintain selection of the DR populations (Figure 1A,B). 
To confirm that DR-PDAC cells were indeed more resistant to drug treatment than the 
parental cell line (PCL), we analyzed cell survival by colony formation assays. PCL- and DR-
PDAC cells were cultured for 24 hours with sub-optimal doses of gemcitabine and then allowed to 
grow in complete medium until they formed visible colonies (Figure 1C,D). Treatment with 
gemcitabine reduced the number of colonies in a dose dependent-manner in PCL cells, whereas DR 
cells were resistant to the lower dose of gemcitabine and less sensitive to the higher dose (Figure 
1C,D). Analysis of cell death by trypan blue cell count or by immunofluorescence analysis of the 
cleaved/activated form of caspase-3 confirmed that gemcitabine was more cytotoxic for PCL- than 
DR-PDAC cells (Supplementary Figure 1B,C). Collectively, these results indicate that the selected 
cell populations have acquired a drug-resistant phenotype. 
 
PKM splicing is regulated in DR-PDAC cells 
Recent evidence suggests a key role for mis-regulation of AS in the acquisition of oncogenic 
features and drug-resistance by human cancer cells (5-8). Thus, we tested whether PCL- and DR- 
PDAC cells display changes in splice variants of a subset of cancer-relevant genes. We selected a 
group of genes whose AS was reported to promote oncogenic features in cancer cells, such as the 
apoptotic genes CASP9 (25), CASP2 (26), BCL-X (27), BIM (28) and FAS (29) (Figure 2A and 
? ?
Supplementary Figure 2A), genes involved in DNA repair and drug resistance, such as USP5 (30) 
and MKNK2 (31,32) (Figure 2B and Supplementary Figure 2B), genes affecting basal metabolism, 
such as PKM (22) (Figure 2C), genes involved in cell migration and invasion, such as RON (10), 
CD44 (5), and c-MET (33) (Figure 2D and Supplementary Figure 2C) or the cell cycle gene 
CCND1 (34) (Figure 2E). RT-PCR analysis showed that AS of most of these genes was either 
unchanged between PCL- and DR-PDAC cells (CASP2, CCND1, c-MET, USP5, MKNK2 and 
RON) or not modulated in the same direction in DR-PDAC cell lines  (CASP9, BCL-X, BIM, CD44 
and FAS) (Figure 2 and Supplementary Figure 2). On the contrary, splicing of the PKM2 variant 
was favoured with respect to PKM1 in both DR-PDAC cell lines (Figure 2C), suggesting that 
modulation of PKM AS correlated with acquisition of drug resistance in PDAC cells. 
 
PKM2 protein is up-regulated in DR-PDAC cells and correlates with relapse free survival in 
PDAC patients 
We focused on the regulation of PKM AS because growing evidence supports a key role for this 
splicing event in tumorigenesis (22,35). The PKM2 splice variant is prevalently expressed in cancer 
cells (22,36), where it regulates processes spanning from cell metabolism (22,24), to transcription 
(23), cell cycle (37) and cell death (38,39). Differential expression of PKM1 and PKM2 in DR-
PDAC cells was confirmed by RT-PCR analysis using primers positioned either in exon 9 (PKM1) 
or 10 (PKM2) to amplify each splice variant (Figure 3A). Furthermore, the switch in PKM splice 
variants was confirmed at the protein level, as DR-PDAC cells expressed higher levels of PKM2, 
whereas PKM1 was almost undetectable with respect to PCL-PDAC cells (Figure 3B). Notably, 
PANC-1 cells, which are more resistant to gemcitabine (Supplementary Figure 1A), also express 
higher levels of PKM2 and lower levels of PKM1 than the more sensitive Pt45P1 cells (Figure 3C). 
These observations indicate that the DR phenotype of PDAC cells correlates with increased 
expression of PKM2. 
? ?
To assess the relevance of PKM2 in vivo, we investigated its expression levels by 
immunohistochemistry in a cohort of 42 patients diagnosed with primary PDAC in the absence of 
metastases, who received radical surgery and subsequent gemcitabine-based adjuvant treatment. 
Our hypothesis was that patients expressing high levels of PKM2 could be more resistant to 
gemcitabine and display worse clinical outcome. The anti-PKM2 antibody was validated by 
immunofluorescence and Western blot analyses of PANC-1 cells silenced for PKM2 and with 
mouse tissues expressing (embryonic) or not (adult) PKM2 (Supplementary Figure 3A-C). Titration 
analysis established 1: 1600 as the optimal dilution for immunohistochemistry (Supplementary 
Figure 3D). The neoplastic lesions of all 42 samples (100%) showed cytoplasmic PKM2 staining 
(Figure 3D), whereas non-neoplastic pancreatic tissue occasionally displayed very weak PKM2 
staining in normal ductal and acinar cells (Supplementary Figure 3D). A linear score of staining 
(range 0-5) was assigned to each sample (see Materials and Methods) and patients were subdivided 
in two groups: the “low PKM2” group comprised 16 samples characterized by weak PKM2 staining 
(i.e. ?3) (Figure 3D, upper panels), whereas the “high PKM2” group comprised 26 samples 
displaying stronger PKM2 staining (i.e. >3) (Figure 3D, lower panels). No differences regarding 
age, sex and pathological features (mean tumour size, grade, stage and resection margins) were 
found between the two groups (Supplementary Table 1). However, the recurrence free survival 
(RFS), defined as the time elapsing from surgery to disease recurrence, was significantly shorter in 
patients with “high PKM2” (mean 11.6 months) as compared with the “low PKM2” group (mean 
19.8 months; p=0.04; Supplementary Table 1). Accordingly, RFS estimated by Kaplan-Meier curve 
was significantly shorter in the first group (Figure 3E), and PKM2 was the only risk factor 
significantly associated with shorter RFS at a Cox proportional-hazards regression (HR 1.12; 95% 
CI 1-4.4; p=0.04). These data suggest that tumors with higher PKM2 basal expression display more 
aggressive behavior and worse response to chemotherapy. 
 
Modulation of PKM splicing impairs drug resistance of DR-PDAC cells 
? ?
AS can be modulated in live cells by antisense short oligonucleotides (ASOs) directed 
against a specific regulatory region (40). In the case of PKM, an ASO targeting exon 10 could 
efficiently induce splicing of PKM1 at the expense of PKM2 (38). We used this tool to modulate 
PKM splicing in PDAC cells and to evaluate the contribution of PKM2 to the DR phenotype. RT- 
PCR and western blot analyses indicated that AS of endogenous PKM could be efficiently 
modulated by transfection of the ASO in PDAC cells (Figure 4A,B). Analysis of cell death by 
immunofluorescence for the cleaved/activated form of caspase-3 (Figure 4C), showed that ASO-
mediated switching of PKM AS in favour of PKM1 increased the sensitivity of DR-PDAC cells to 
gemcitabine without affecting the basal level of cell death (Figure 4C). Furthermore, 
overexpression of PKM2 in PCL-PDAC cells protected them from gemcitabine-induced cell death 
(Supplementary Figure 4A,B). These results indicate that PKM2 expression in DR-PDAC cells is 
required to maintain gemcitabine resistance. 
 
PTBP1 is up-regulated in DR-PDAC cells 
Three hnRNPs (hnRNPI/PTBP1, hnRNPA2/B1 and hnRNPA1) were shown to cooperate to 
suppress exon 9 inclusions in the PKM transcript, leading to exon 10 inclusion and expression of 
the PKM2 variant (35). Notably, these splicing factors were up-regulated in brain tumors and their 
expression strongly correlated with that of PKM2 (35). Thus, we investigated if the expression of 
these hnRNPs was altered in DR-PDAC cells with respect to PCL cells. We found that only PTBP1 
was markedly up-regulated in both DR-Pt45P1 and DR-PANC-1 cells (Figure 5A,B). The highly 
homologous PTBP2 protein was not detected in PDAC cells (Figure 5A,B). By contrast, 
hnRNPA2/B1 levels were unchanged in PCL- and DR-PDAC cells, whereas hnRNPA1 was up- 
regulated in DR-PANC-1 (Figure 5B) but slightly reduced in DR-Pt45P1 (Figure 5A). Furthermore, 
PTBP1 expression correlated with sensitivity of PDAC cells to gemcitabine, as it was higher in 
PANC-1 cells than in Pt45P1 cells (Supplementary Figure 5A). The correlation between PTBP1 
expression and PKM2 splicing in both DR-PDAC cell lines was specific, as demonstrated by 
? ?
western blot analysis of other cancer-related SR proteins and hnRNPs in PCL- and DR- PDAC cells, 
which showed either marginal or inconstant alterations. For instance, up-regulation of SRSF1 was 
detected in DR-Pt45P1 cells but not in DR-PANC-1 cells (Supplementary Figure 5B), possibly 
because PANC-1 cells are more resistant to drug treatment and express higher basal levels of 
SRSF1. By contrast, SRSF6 was strongly up-regulated in DR-PANC-1 but slightly reduced in DR-
Pt45P1 (Supplementary Figure 5B). Thus, up-regulation of PTBP1 appears to specifically correlate 
with regulation of PKM2 splicing in DR-PDAC cells. 
 
PTBP1 binds in vivo PKM intron 8 and its downregulation impairs PKM2 expression and 
sensitizes DR-PDAC cells to drug-induced cell death 
To test whether PTBP1 was recruited to the PKM transcript more efficiently in DR-PDAC 
cells, we analyzed in vivo binding by CLIP assays in PCL- and DR -Pt45P1 cells, silenced or not 
for PTBP1 (Figure 6A). Binding of PTBP1 in intron 8 of PKM favours skipping of exon 9 in the 
mature transcript (35), thereby generating the PKM2 isoform. Thus, we analyzed two regions in 
intron 8, named A and B (Figure 6A), which were identified as high PTBP1-bound sequences by 
CLIP-seq analysis (41). CLIP assays showed that PTBP1 was recruited more efficiently to PKM 
intron 8 in DR-Pt45P1 cells with respect to PCL-Pt45P1 cells (Figure 6A). Increased binding was 
specific and likely dependent on the higher expression of PTBP1 in DR cells, as it was suppressed 
by knockdown of the protein to levels comparable with those expressed in PCL cells (Figure 6A). 
Thus, up-regulation of PTBP1 in DR-PDAC cells leads to increased recruitment of this splicing 
factor to PKM intron 8. 
To evaluate the contribution of PTBP1 to the regulation of the PKM2 variant, we analyzed 
PKM AS in DR-PDAC cells knocked down for PTBP1. Knockdown of endogenous PTBP1 
increased PKM1 splicing in DR-PDAC cells, resulting in a switch in PKM1 and PKM2 protein 
levels (Figure 6B). These results confirm that up-regulation of PTBP1 promotes PKM2 splicing in 
DR-PDAC cells. To test whether PTBP1 affected additional splicing events in DR- PDAC cells, we 
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analyzed a subset of genes whose AS is regulated by this splicing factor in other cell types 
(41,42,43). RT-PCR analysis indicated that only the FGFR2 IIIc variant correlated with the higher 
expression of PTBP1 in both DR-PDAC cell lines (Supplementary Figure 6A). However, silencing 
of PTBP1 did not affect this splicing event (Supplementary Figure 6E), indicating that expression of 
FGFR2 IIIc correlates with but is not dependent on high PTBP1 expression in DR-PDAC cells. By 
contrast, splicing of EZH2, CTTN, RASSF8, MINK1, EIF4G2, FAM38A, CCDC138 and TPM1 was 
either similar in PCL- and DR-PDAC cells or altered in one of the two DR cell lines 
(Supplementary Figure 6A-C). These findings indicate that splicing of PKM is specifically 
modulated by PTBP1 over-expression in DR-PDAC cells. 
To investigate whether PTBP1 expression is required for the resistance of DR-PDAC to 
chemotherapeutic treatments, we analyzed gemcitabine-induced cell death in PTBP1-depleted DR- 
PDAC cells. Down-regulation of PTBP1 expression significantly rescued the sensitivity of DR- 
PDAC cells to treatment with gemcitabine, reaching levels of cell death similar to those of PCL-
PDAC cells (Figure 6C,D). We also tested resistance to cisplatin as prototype of a class of drugs 
currently used in clinical trials of combined chemotherapy for advanced PDAC (44). Cell death 
analysis showed that DR-PDAC cells were more resistant to cisplatin treatment than PCL-PDAC 
cells (Supplementary Figure 7A). However, switching PKM splicing by either ASO transfection 
(Supplementary Figure 7B) or knockdown of PTBP1 (Supplementary Figure 6C) rescued sensitivity 
to cisplatin, suggesting that the PTBP1/PKM2 axis is involved in PDAC cell survival to multiple 
cytotoxic drugs. 
Collectively, these results indicate that high PTBP1 expression levels are required for 
maintenance of the DR phenotype of PDAC cells and suggest that this splicing factor mainly 
confers drug resistance to PDAC cells through the promotion of PKM2 splicing. 
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Discussion 
PDAC is a human cancer characterized by very poor prognosis. Chemotherapeutic 
approaches are largely ineffective and treatment with the elective agent gemcitabine slightly 
improves survival in patients with advanced disease, but does not represent a cure (1). For this 
reason, understanding the biology of PDAC cells might shed light on novel therapeutic strategies 
for the management of advanced PDAC. In this work, we show that chronic gemcitabine treatment 
leads to isolation of DR-PDAC cells that display higher resistance not only to gemcitabine, but also 
to cisplatin, a prototype of cytotoxic drugs largely used in human cancer therapy, including PDAC 
(44). These findings suggest that hostile stimuli promote the adaptive capabilities of PDAC cells, 
thus favouring the selection of drug- resistant populations. 
In order to elucidate the molecular mechanisms involved in the acquisition of the DR 
phenotype by PDAC cells, we focused on AS regulation because this process is emerging as a key 
determinant of eukaryotic cell plasticity (45) that is often altered in human cancers (5-8). 
Furthermore, genotoxic stresses, like those imposed by chemotherapeutic treatments, can finely 
tune the expression of splice variants that protect cancer cells (15). In this regard, our study 
identifies PKM splicing as a novel contributor to drug resistance acquired by PDAC cells during 
chronic chemotherapeutic treatment. We found that promotion of PKM2 is the AS event that 
correlates more closely with drug resistance among a subset of cancer-relevant splicing events 
analyzed. Importantly, PKM2 splicing and expression are functionally relevant for the resistance to 
chemotherapeutic treatment, as switching splicing toward PKM1 by ASO transfection restored 
sensitivity of DR-PDAC cells to both gemcitabine and cisplatin. These results point to PKM2 as a 
new potential prognostic marker and therapeutic target for PDAC. In support of this hypothesis, we 
also found that high PKM2 expression was the only risk factor significantly associated with shorter 
RFS in patients receiving radical surgery and adjuvant chemotherapy with gemcitabine. These 
results suggest that increased PKM2 expression might be responsible for lower response of residual 
cancer cells to chemotherapy. Although we did not find a significant correlation between PKM2 
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expression and overall survival, the observed trend suggests that patients expressing higher PKM2 
levels also have a shorter survival rate (Supplementary Table 1). Studies with a larger cohort of 
patients will be required to further assess whether or not PKM2 can be used as marker for 
prediction of severity of the disease and response to treatments. 
The role of PKM2 in cancer is not fully elucidated yet. Nevertheless, several observations 
pointed out that this splice variant is expressed at higher levels in cancer tissues versus their normal 
counterparts (22,35). PKM2 protein was proposed as a potential molecular marker of PDAC, as 
immune reactivity toward this isoform was elevated in blood from patients and positively correlated 
with metastatic disease (46). We now show that PKM2 is barely detectable in areas of pancreas 
with normal glands, whereas its expression is increased in neoplastic lesions. Moreover, our 
findings document that up-regulation of PKM2 in DR-PDAC cells is required for survival in the 
presence of gemcitabine or cisplatin. Notably, depletion of PKM2 in several human cancer cell 
lines caused apoptosis even in the absence of chemotherapeutic treatments (38,39). This effect was 
cancer-specific, as depletion of PKM2 in non-cancerous cells did not affect their viability (39). In 
the case of DR-PDAC cells, however, depletion of endogenous PKM2 per se does not trigger cell 
death, indicating that PDAC cells are somewhat less dependent on this enzyme for viability. 
Nevertheless, PKM2 was strictly necessary to withstand genotoxic stress in DR-PDAC cells. 
Importantly, PKM2 expression has been linked to response to chemotherapy also in lung cancer, as 
its depletion sensitized to apoptosis triggered by chemotherapeutic treatment in mouse xenograft 
models (47). Our work also supports this scenario and suggests that modulation of PKM splicing by 
ASO treatment is a potential therapeutic tool to increase the efficacy of standard chemotherapy in 
advanced PDAC. This strategy might represent a promising approach, as ASOs are already in 
clinical trials for other splicing-caused diseases and improvement of their design and administration 
protocols might insure their use in cancer therapy in the near future (40). 
Aberrant expression of several splicing factors correlates with cancer onset, progression 
and/or response to therapeutic treatments (48). Our findings indicate that the switch in PKM AS 
? ??
correlates with the up-regulation of PTBP1 in DR-PDAC cells. A role for PTBP1 in PKM splicing 
was already shown in glioblastoma, where this splicing factor acted in concert with hnRNP A1 and 
A2/B1 to promote PKM2 splicing (35). However, we found that neither of these hnRNPs was 
consistently modulated in DR-PDAC cells. Moreover, knockdown of PTBP1 to mimic the levels 
observed in PCL-PDAC cells was sufficient to raise PKM1 levels to those present in parental cells. 
Thus, PTBP1 is the main player in the regulation of PKM AS during the acquisition of the DR 
phenotype by PDAC cells. Importantly, the effect of PTBP1 on PKM2 splicing in PDAC cells 
appears to be direct, as it correlates with the extent of PTBP1 recruitment to PKM intron 8. 
Furthermore, its effect on PKM AS can account for the acquired resistance to genotoxic drugs, as 
DR-PDAC cells knocked down for PTBP1 switched AS in favour of PKM1 and became sensitive 
to gemcitabine and cisplatin like PCL-PDAC cells. Although the pro-survival effect of PTBP1 up- 
regulation in PDAC cells might also involve other targets of this splicing factor, our observations 
suggest that splicing of PKM2 represents the main player. Indeed, by monitoring a group of splice 
variants previously shown to be target of PTBP1 in other cellular systems (41,42,43), we did not 
observe striking and consistent changes correlating with the DR-PDAC phenotype. The only 
relevant change observed was promotion of the FGFR2 IIIc variant, which, however, was 
unaffected by knockdown of PTBP1 in DR-PDAC cells. Furthermore, selectively restoring the PCL 
pattern of PKM splicing by ASO transfection almost completely rescued the sensitivity of DR- 
PDAC cells to genotoxic stresses. Thus, our results suggest that PKM AS is particularly sensitive to 
changes in the expression levels of PTBP1 in PDAC cells and that this splicing event represent a 
key resource for these cells to acquire drug resistance. 
In conclusion, our work characterizes a novel PTBP1/PKM2 pro-survival pathway triggered 
by chronic treatment of PDAC cells with gemcitabine. Interfering with this axis by repressing 
PKM2 splicing or PTPB1 expression can restore sensitivity of DR-PDAC cells to drug treatment. 
Since development of therapeutic ASOs is already a clinical approach for other human diseases (40), 
? ??
these findings might represent a promising strategy to improve therapeutic approaches for PDAC 
and to impact the resistance of cancer cells to current treatments. 
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Materials and methods 
Cell culture, treatments and transfections 
Pt45P1 and PANC-1 cells were obtained from the Centre for Molecular Oncology, Barts Cancer 
Institute (London, UK) in 2004 and authenticated in 2012. DR cells  were obtained by treating PCL 
with 10 ?M gemcitabine continuously for 7 days (medium replaced every 72 hours) and then 
released in normal medium for 15 days. Resistant clones were pooled, amplified and cultured by 
performing a 24 hour-pulse of 10 ?M gemcitabine every other week to maintain selection. PCL and 
DR cells were maintained in RPMI 1640 (Lonza, Switzerland) supplemented with 10% FBS, 
gentamycin, penicillin and streptomycin. Gemcitabine (Eli Lilly & Company, IN, USA) and 
cisplatin (Sigma-Aldrich, MO, USA) were dissolved in water. For ASO transfection, cells were 
transduced by scraping delivery according to manufacturer’s instructions (Gene Tools, Oregon, 
USA) with PKM2 or control ASO (10 ?M for DR-PANC-1 cells, 15 ?M for DR-Pt45P1 cells). For 
RNA interference, cells were transfected twice with 30 nM PTBP1 siRNAs (On target plus human 
PTBP1 5725 siRNA, Dharmacon, CO, USA) using Lipofectamine RNAiMAX and Opti-MEM 
medium (Life Technologies, California, USA) according to manufacturer’s instructions. 
 
Colony formation assay and cell death analyses 
Single cell suspensions were plated in 6-well plates (500 cells/plate for Pt45P1, 750 cells/plate for 
PANC-1). After 1 day, cells were treated for 24 hours with gemcitabine. Fresh medium was 
replaced every 48h. After 10-12 days, cells were fixed in methanol for 10 min, stained overnight 
with 5% Giemsa (Sigma-Aldrich), washed in PBS and dried. Pictures were taken using a digital 
camera and colonies were counted. For cell death analyses, cells were seeded at 70% confluence 
and treated as described for 72 h. Cells were then washed in PBS and either trypsinized and 
incubated with 0.4% Trypan Blue Stain (Sigma-Aldrich) or processed for caspase 3 
immunofluorescence using anti-cleaved caspase-3 antibody (1:500; Sigma-Aldrich) as previously 
described (31,49). Positive cells were then counted using the Thoma’s chamber (trypan blue) or 
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fluorescence microscopy (caspase 3). Five random fields were chosen for each treatment and at 
least 200 cells/field were counted.
Polymerase chain reaction (PCR) analyses 
RNA was extracted using TRIzol (Life Technologies) according to the manufacturer’s instructions. 
After digestion with RNase-free DNase (Life Technologies), 1 ?g of total RNA was 
retrotranscribed using M-MLV reverse transcriptase (Promega, WI, USA), used as template for 
conventional PCR reactions (GoTaq, Promega). Products were analysed on agarose or acrylamide 
gels. RT-PCR images were collected with Biorad Universal Hood II using Image Lab software. 
Real-time quantitative PCR (qPCR) analysis was performed using LightCycler 480 SYBR Green I 
Master and the LightCycler 480 System (Roche, Germany), according to the manufacturer’s 
instructions. Primers used are listed in Supplementary Table 2. 
 
Protein extracts and western blot analysis 
Cells were resuspended in RIPA buffer: 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 1 mM dithiothreitol, 0.5 mM NaVO4, and protease 
inhibitor cocktail (Sigma-Aldrich). After 10 min on ice, extracts were centrifuged for 10 min at 
12,000 g ,supernatants were collected and used for western blot as described (49). Primary antibody 
incubation (1:1000) was carried out with the following antibodies: PKM1, hnRNPA1, 
hnRNPA2/B1, hnRNPC1/C2 (Sigma-Aldrich); PKM2 (Cell Signaling Technology, MA, USA); 
PTBP1, SRSF1, SRP20, SRp40/p55/p75 (Santa Cruz Biotechnology, CA, USA); hnRNPF/H 
(Abcam, UK). PTBP2 antibody was a generous gift of Professor Douglas L. Black (UCLA, CA). 
Images of the western blot were acquired as TIFF files. 
Immunohistochemistry analysis 
? ??
Immunohistochemistry (IHC) was performed as previously described (31). Briefly, formalin-fixed, 
paraffin-embedded tissue samples obtained from 42 primary non metastatic PDAC patients 
receiving surgery with radical intent were investigated for PKM2 expression, upon informed 
consent. All patients received gemcitabine-based adjuvant therapy after surgery. Clinical and 
histopathological data, time of tumor recurrence and survival for each patient were recorded. IHC 
was performed on 4?m-thick sections. Antigen retrieval was carried out with EDTA at pH8 (60 min 
at room temperature). Staining was carried out using anti PKM2 antibody (1:1600, Cell Signaling), 
visualized by Envision-Flex (Dako, Denmark). Staining of PKM2 in neoplastic cells was scored 
based on distribution and intensity. Distribution was scored as 0 (0%), 1 (1-50%) and 2 (51-100%). 
Intensity was scored as 0 (no signal), 1 (mild), 2 (intermediate), 3 (strong). Values were summed in 
a total score from 0 to 5. Samples were classified as “low PKM2” expression (score ?3) and as 
“high PKM2” expression (score >3). Statistical analysis was performed by MedCalc® 9.6 
(www.medcalc.be). Differences for continuous variables were evaluated by t-test and for 
categorical variables by Fisher’s test. Analysis of recurrence-free survival (RFS) and of overall 
survival was performed by Kaplan-Meier method and analysed by Log-rank test. Univariate and 
multivariate analyses for risk factors affecting survival were performed by Cox-proportional 
hazards regression model test; a p value <0.05 was considered as statistically significant 
(Supplementary Table 1). Images were taken from a Zeiss axioskop 2 plus and elaborate with 
software Zeiss axiovision. 
 
UV-crosslinked and RNA immunoprecipitation (CLIP) assays 
For CLIP assays, cell extract were performed as previously described (50,51). Half extract (1mg) 
was treated with Proteinase K for 30 min at 37°C and RNA was purified (input). The remaining half 
(1 mg) was diluted to 1 ml with lysis buffer and immunoprecipitated by using anti-PTBP1 (Santa 
Cruz Biotechnology) antibody or IgGs (negative control), in presence of protein-G magnetic 
dynabeads (Life Technologies). 10 ?l/ml of RNaseI 1:1000 (Life Technologies) were added. After 
? ??
immunoprecipitation and washes (50,51), an aliquot (10%) of the sample was kept as control of 
immunoprecipitation while the rest was treated with 50?g of Proteinase K and incubated for 1hr at 
55°C. RNA was then isolated. 
 
Image acquisition and manipulation 
Images in Figure 1B were taken from an inverted microscope (IX70; Olympus) using an LCA ch 
40×/0.60 objective.  Adobe Photoshop and Illustrator were used for composing the panels. 
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Figure legends: 
Figure 1: Chronic treatment with gemcitabine selects DR-PDAC cells 
(A) Schematic representation of the protocol used to obtain drug-resistant (DR) PDAC cells from 
parental PDAC cells (PCL). (B) Representative phase contrast images of PCL- and DR-Pt45P1 (left 
panels) or PANC-1 (right panels) cells (40x magnification). (C-D) Representative images of the 
colony assay (upper panels) performed in PCL- and DR-Pt45P1 (C) or PANC-1 cells (D). (C-D). 
Bar graphs (bottom panels) show the percentage of survival with respect to untreated cells from 
three experiments (mean ± SD), as assessed by colony formation. Brackets indicate statistical 
comparison of the indicated samples. Statistical analyses were performed by the paired Student’s t-
test. ** p ? 0.01. 
 
Figure 2: The PKM2 splice variant is promoted in DR-PDAC cells 
(A-E) RT-PCR analysis in PCL- and DR-Pt45P1 or PANC-1 cells of splice variants encoded by the 
indicated cancer-related genes. Schematic representation of the cancer-related AS events analyzed 
is shown in the upper panels. Exons (boxes) and introns (lines) are indicated. Black arrows indicate 
primers used for the RT-PCR analysis (bottom panels). (C) RT-PCRs of PKM gene were followed 
by PstI digestion in order to distinguish the amplicons. Bar graphs represent the percentage of the 
indicated AS variants, as assessed by densitometric analysis of the bands. Statistical analyses were 
performed by the paired Student’s t-test comparing PCL- and DR-PDAC cells values (mean ± SD, 
n=3, **p<0.01, ns: not significant). (F) HPRT was used as loading control for RT-PCR analyses in 
panels A-E.  
 
Figure 3: PKM2 protein expression in PDAC cells and PDAC tissues 
RT-PCR (A) and Western blot (B) analyses of PKM1 and PKM2 splicing variants in PCL- and DR-
PDAC cells. Schematic representation of the PKM gene is shown in the upper panel, black arrows 
? ??
indicate the specific primers used to amplify the PKM1 and PKM2 in PCL- and DR-PDAC cells. 
HPRT and PKM exon 5-6 region were used as loading control (A). Coomassie staining was used as 
loading control (B). (C) Western blot analysis of PKM1 and PKM2 protein in PCL-PDAC cells. 
Coomassie staining was used as loading control. (D) Representative images of PKM2 
immunohistochemistry in PDAC tissues (10X magnification). Upper panels show neoplastic glands 
with weak staining (low PKM2 group; score ?3), bottom panels show neoplastic glands with strong 
staining (high PKM2; group score >3). (E) Analysis of recurrence free survival (RFS) of PDAC 
patients. Low PKM2 group comprised 16 patients (continuous line) while high PKM2 group 
comprised 26 patients (dotted line); p=0.04 at log-rank test. 
Figure 4: Modulation of PKM splicing enhances gemcitabine-induced cell death in DR-PDAC 
cells
(A-B) RT-PCR (A) and western blot (B) analyses of PKM splicing variants performed in DR-
Pt45P1 (left panels) and DR-PANC-1 (right panels) cells transduced with a control ASO (CTRL 
ASO) or with a specific ASO used to revert PKM splicing (PKM2 ASO) in favour of PKM1 (see 
Supplementary Table 1).  (A) Bar graphs represent the percentage of PKM2 variant, as assessed by 
densitometric analysis of the bands. Statistical analyses were performed by the paired Student’s t-
test comparing DR-PDAC cells values with those obtained in PCL-PDAC cells while brackets 
indicate statistical comparison of the indicated samples (** p ? 0.01; ns: not significant). (B) 
Coomassie staining was used as protein loading control. (C) Bar graphs show the percentage of cell 
death from three experiments (mean ± SD) as assessed by immunofluorescence analysis of the 
cleaved form of caspase-3 in PCL- and DR-PDAC cells transduced with CTRL or PKM2 ASO and 
treated as indicated. Statistical analyses were performed by the paired Student’s t-test, comparing 
DR-PDAC cell values with those obtained in PCL-PDAC cells treated with gemcitabine, while 
brackets indicate statistical comparison of the indicated samples (* p ? 0.05, ** p ? 0.01, ns: not 
significant). 
? ??
 
Figure 5: PTBP1 is up-regulated in DR-PDAC cells 
(A-B) Western blot analysis of PTBP1, PTBP2, hnRNPA1 and hnRNPA2/B1 protein expression in 
PCL- and DR-Pt45P1 (A) or PANC-1 cells (B). Coomassie staining was used as loading control.  
 
Figure 6: PTPB1 up-regulation is required for PKM2 splicing and gemcitabine resistance in 
DR-PDAC cells 
(A) UV crosslink immunoprecipitation (CLIP) of PTBP1 performed in PCL- or DR-Pt45P1 PDAC 
cells transfected with either a control (si-ctrl) or PTBP1 (si-PTBP1) siRNAs, in presence of RNaseI 
(1:1000). Associated PKM pre-mRNA was quantified by qPCR, black arrows indicate primers used 
to amplify A and B regions (upper panels; see Supplementary Table 1). Data are represented as 
percentage of input (bottom panels; mean ± SD; n=3). Statistical analyses were performed by the 
paired Student’s t-test (** p ? 0.01, ns: not significant). PTBP1 silencing in DR-Pt45P1 cells and IP 
efficiency were assessed by western blot analysis. (B) RT-PCR and western blot analyses to 
evaluate PKM1 and PKM2 expression in DR-PDAC cells transfected with either ctrl or PTBP1 
siRNAs. Bar graphs represent the percentage of PKM2 variant, as assessed by densitometric 
analysis of the bands. Statistical analyses were performed by the paired Student’s t-test comparing 
the values of DR- PDAC cells transfected with si-ctrl with those obtained in DR-PDAC cell 
transfected with si-PTBP1 siRNA (** p ? 0.01; (upper panels, mean ± SD, n = 3, ** p ? 0.01). (B) 
PTBP1 silencing was assessed by western blot analysis. Coomassie staining was used as loading 
control. (C-D) Western blot analyses assessing PTBP1 expression levels in PCL- and DR-Pt45P1 or 
PANC-1 PDAC cells transfected with ctrl or PTBP1 siRNAs. Coomassie staining was used as 
loading control. (C-D) Bar graphs show the percentage of cell death from three experiments (mean 
± SD) as assessed by immunofluorescence analysis of the cleaved form of caspase-3 in PCL-, DR-
PDAC cells described in panel C-D and treated as indicated for 72 hours. Statistical analyses were 
performed by the paired Student’s t-test comparing DR-PDAC cell values with those obtained in 
? ??
PCL-PDAC cells treated with gemcitabine, while brackets indicate statistical comparison of the 
indicated samples (** p ? 0.01, ns: not significant). 
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